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Beides! führt! zum! sog.! Replikationsstress,! das! heisst! einer! Verlangsamung! oder! Pausieren! des!
Replikationsprozesses,!oft!verbunden!mit!eine!strukturelle!Umformung!der!Replikationsgabel!O!wobei!
die!Replikationsgabel!aktiv!von!einer!dreiarmigen!in!eine!vierarmige!Struktur!überführt!wird.!Dieser!
Prozess! fördert! die! zelluläre! Replikationsstresstoleranz! und! die! DNAOReparatur! während! der!





Einer! dieser! Mechanismen! nennt! sich! DNA! Damage! Response! (DDR),! eine! Signalkaskade! aus!
verschieden! Kinasen! und! UbiquitinOLigasen.! Diese! Enzyme! modifizieren! das! Chromatin! in! der!
Umgebung!von!DNAODoppelstrangbrüchen!und!bewirken!so!die!Akkumulation!von!Reparaturproteinen!
an! der! Schadensstelle.! Homozygote! Mutationen! in! bestimmten! DDR! Genen! verursachen! schwere!
Erbkrankheiten,! gekennzeichnet! durch! Empfindlichkeit! gegenüber! Röntgenstrahlung,! ein! erhöhtes!
Krebsrisiko,! Immunschwäche! und! neurologische! Fehlbildungen.! Auch! Träger! von! heterozygoten!
Mutationen!in!diesen!Genen!zeigen!ein!deutlich!erhöhtes!Risiko!für!BrustO!und!andere!Krebsarten.!
Ein! zentrales! Enzym! der! DDR! ist! die! UbiquitinOLigase! RNF168,! welche! Ubiquitinketten! an! den! NO
terminalen!Bereich!der!HistonOVarianten!H2A/H2AX!in!der!Nähe!von!Doppelstrangbrüchen!konjugiert.!
Diese!Ketten!dienen! ihrerseits!als!Andockungsstelle! für!die!Reparaturenzyme!53BP1!und!BRCA1.! In!
dieser! Arbeit! präsentiere! ich! unsere! Beobachtung,! dass! die! Ubiquitinierung! von! Histon! H2A/H2AX!
durch! RNF168! notwendig! ist! um! eine! effiziente! DNA! Replikation! zu! garantieren.!Wir! zeigen,! dass!
RNF168!an!aktiven!Replikationsgabeln!in!der!Zelle!akkumuliert!und!dass!seine!Enzymaktivität!benötigt!
wird,!um!blockierte!Replikationsgabeln!neu!zu!starten!und!so!vor!nukleolytischem!Abbau!zu!schützen.!
Ausserdem! demonstrieren! wir,! dass! strukturell! umgeformte! Replikationsgabeln! vollständig!
chromatinisiert!sind!und!somit!von!RNF168!modifiziert!werden!können.!Da!auch!andere!Proteine!der!
DDR! dieselbe! Replikationsfunktion! wie! RNF168! zeigen,! proponieren! wir! die! Prozessierung! von!
umgeformte! Replikationsgabeln! als! alternative! Funktion! der! klassische! DDR! Enzyme,! die! damit!
entscheidend!zur!Stabilität!der!genetischen!Information!in!unseren!Zellen!beitragen.!
Weitere! Kapitel! meiner! Doktorarbeit! enthalten! Beobachtungen! zur! Funktion! verschiedener!
Ubiquitinketten!und!diverser!anderer!DNA!Reparaturenzyme!während!der!Replikation.!!








surprising! that! copying! this! vast! amount! of! information! during! a! single! cell! cycle! is! a! gigantic!
undertaking!and!subject!to!innumerable!challenges.!!
During! any! normal! SOphase,! our! replicative!machinery! is! confronted! with! countless! obstacles! that!


















polyOubiquitination!of!histones!H2A! is!also!essential! for!efficient!DNA!replication! in!unperturbed!SO
phase.!We! show! that!RNF168! localizes! to! a! subset! of! active! replication! factories! in! cells! devoid!of!











This! thesis! highlights! the! remarkable! structural! similarities! between! DNA! DSBs! and! the! doubleO






In! 2011! Douglas! Hanahan! and! Robert! Weinberg! defined! genome! instability! and! mutation! as! an!












of!human!cells! (Friedberg!2008).! Since! then!many!DNA!damaging!agents!and!processes!have!been!
discovered! that!either! change! the! sequence!of! the!DNA!directly!or!alter! it!by!affecting! the!cellular!
processes!of!DNA!replication!and!repair!(Lord!&!Ashworth!2012).!The!causes!of!genome!instability!can!
be! broadly! divided! by! their! origin! as! exogenous! and! endogenous.! Both! types! will! be! discussed!
separately!below,!even! though! there! is! always!a! certain!mechanistic! crossOtalk!between! these! two!
categories.!
3.1.1.1.! Exogenous,
The! international! agency! for! research! on! cancer! (IARC)! currently! lists! 120! substances! that! are!
mutagenic! and! carcinogenic! to! humans! and! an! additional! 81! that! are! probably! carcinogenic! (IARC!
2012).!Hence,!the!scope!of!this!subchapter!is!not!to!discuss!all!of!these!agents!individually!but!rather!
to!highlight!certain!important!classes!of!DNA!damaging!agents.!!
One!of! the! first! exogenous! sources!of!DNA!damage!was!already!postulated! in!1775!by! the!English!
surgeon!Percival!Pott!–!almost!two!hundred!years!before!the!discovery!of!the!DNA!double!helix.!Pott!
observed!a!strikingly!high!incidence!of!scrotum!cancers!in!chimney!sweeps!and!proposed!a!link!to!their!
frequent!exposure! to! soot.! This!marked! the! first! recorded!evidence! for! an!environmental! cause!of!








term! alkylation.! The! resulting! DNA! adducts! can! interfere! with! replication! fork! progression,! which!




of! these! compounds! like! alkylsulphonates! or! temozolomide! are! currently! used! as! cancer!
chemotherapeutics.!The!second!category!are!bifunctional!alkylating!agents,!which!have!two!reactive!
sites!and!can!therfore!crosslink!DNA!with!proteins.!Alternatively,! they!can!crosslink!two!DNA!bases!
within! the!same!strand! (intraOstrand!crosslink)!or!on!opposing!DNA!strands! (interOstrand!crosslink).!
InterOstrand!crosslinks!pose!a!particularly!sever!obstacle!for!replication.!Not!surprisingly,!interOstrand!
crosslinking! agents! like!mitomycin! C! or! cisplatin! have! become! prominent! chemotherapeutic! drugs!
(Helleday!et!al.!2008).!















DNA! supercoiling! and! entanglements! through! distinct! enzymatic! activities! and! thereby! release!
torsional!stress!(Pommier!et!al.!2016).!The!cytotoxic!activity!of!topoisomerase!inhibitors!does!not!stem!
from!classical!enzymatic! inhibition,!but! rather! is!a!consequence!of! trapping! topoisomerases!on! the!
DNA,!which! ultimately! results! in! the! formation! of! DNA! double! strand! breaks.! Camptothecin! (CPT)!
derivatives! are! inhibitors! of! topoisomerase! 1! (Top1)! and! form! an! important! group! of!





















organ! systems! remains!a!matter!of!debate! (Tomasetti!&!Vogelstein!2015;!Wu!et!al.! 2016)!modern!




is! Lynch!syndrome,!a!cancer!predisposition!syndrome!caused!by! inactivating!germline!mutations! in!
DNA! mismatch! repair! (MMR)! genes.! The! MMR! pathway! is! responsible! for! the! recognition! and!
correction!of!nonOWatsonOCrick!base!pairs! and! strand!misalignments! that!arise!during!normal!DNA!
replication.!Defects!in!the!MMR!process!lead!to!a!hypermutation!phenotype!and!a!strongly!increased!
risk!for!tumorigenesis,!most!prominently!the!development!of!colon!cancers!(Jiricny!2013;!PeñaODiaz!&!
Rasmussen! 2016).! Hereditary! breast! and! ovarian! cancer! (HBOC)! is! another! prominent! cancer!
predisposition! syndrome! caused!by!mutations! in! the!breast! cancer! susceptibility! genes!BRCA1!and!
























Genome! instability!can!have!severe!consequences! for!our!wellbeing.!Most! importantly! it!drives!the!
process!of!aging!and!the!development!of!cancer!(LópezOOtín!et!al.!2013;!Jeggo!et!al.!2015),!both!of!
which!will!be!discussed!in!this!subchapter.!From!a!superficial!point!of!view!cancerogenesis!and!ageing!



























fact! that! prominent! human! progeria! diseases! such! as!Werner! syndrome,! Cockayne! syndrome! and!







related! accumulation! of! genetic! changes! causes! stochastic! deregulation! of! gene! expression! among!
neighbouring!cells,!which!can!jeopardize!tissue!function!(Aunan!et!al.!2017).!Furthermore,!it!has!been!













activated! in! an! ATPOdependent!manner! by! forming! a! thioster! bond!with! an! E1! activation! enzyme!
(Husnjak! &! Dikic! 2012).! Next,! Ub! gets! transferred! onto! an! E2! enzyme,! again! forming! a! thioester!
intermediate.!In!many!cases!the!E2!appears!to!regulate!the!specific!type!of!Ub!mark!assembled!on!the!
































K63Olinked! chains! are! the! most! prevalent! chain! types! in! human! cells! and! they! are! also! the! most!







has! been! reported! to! assemble! K6Olinked! chains! on! itself! and! on! Histone! H2A.! This! activity! was!
suggested! to! play! a! role! during! DNA! replication! and! repair,! however! its! precise! functional!
consequences!have!not!yet!been!firmly!established!(Morris!&!Solomon!2004;!Kalb!et!al.!2014).!K27!






































modifications! of! histones! and! histoneObinding! proteins! and! prominently! involves! nonOproteolytic!










dependent! DDR.! It! subsequently! recruits! the! serine/threonine! kinase! ATM! (ataxia! telangiectasia!
Figure,3:,The,Ub,dependent,signaling,response,to,DNA,double,strand,breaks,(Modified!from!Thorslund!et!al.,!2015)!





















core! histones! H2A! and! H2A.X! (Gatti! et! al.! 2015).! This! RNF168! mediated! Ub! mark! constitutes! a!
recruitment!platform! for!downstream!DDR! factors,!most!prominently!BRCA1! (Breast!Cancer!1)!and!
53BP1!(p53!Binding!Protein).!BRCA1!and!53BP1!promote!the!activation!of!distinct!pathways!ultimately!
resulting!in!the!repair!of!the!DNA!break!(Doil!et!al.!2009;!AlOHakim!et!al.!2010;!Smeenk!&!Mailand!2016).!




























































Figure, 4:, Nonhomologous, end, joing, (Modified! from!
Schwertman!et!al.,!2016)!
DSBs!formed!in!interphase!are!rapidly!bound!and!protected!
by! the! heterodimeric! Ku! complex.! This! leads! to! the!
recruitment! of! DNAOPKc! in! conjunction! with! the!
endonuclease! Artemis.! Artemis! is! then! activated! through!
DNAOPKc!and!trims!overhangs!at!the!break!site.!53BP1!and!its!
two! interactors! RIF1! and! PTIP! prevent! BRCA1! binding! and!
promote! Artemis! recruitment! to! the! break! site,! thereby!
channelling! the! repair! into! the! NHEJ! pathway.! The! actual!
ligation! is! achieved! through! the! XRCC4OLigase! IV! complex!
which!can!be!assisted!by!PAXX!and/or!XLF!depending!on!the!
precise!structure!of!the!break.!During!G1!the!APC/C!complex!
targets! CtIP! for! proteasomal! degradation! and! thereby!
prevents!HR!repair!in!this!cell!cycle!phase.!The!E3!ligase!RNF8!
assembles!K48!linked!Ub!chains!on!Ku80,!which!promotes!the!







in! highly! accurate! repair.! In! most! cases! the! sister! chromatid! is! employed! to! retrieve! the! missing!
sequences.!This!restricts!HR!to!cell!cycle!stages!when!such!a!repair!template! is!physically!available,!
which! is! only! the! case! during! the! SO! and! G2Ophase! (Ranjha! et! al.! 2018;! Kowalczykowski! 2015).! To!
prevent! this!mechanism! from! running! awry! it!must! be! tightly! regulated.! A! critical! process! for! the!
regulation!of!DSB!repair!is!DNA!end!resection,!which!likely!dictates!pathway!choice!between!NHEJ!and!
HR.!The!initial!phase!of!end!resection!in!HR!is!performed!by!the!structure!specific!endonuclease!MRE11,!
a! component!of! the!MRN! (MRE11/RAD50/NBS1)! complex,! in! conjunction!with!CtIP.!During! this! soO
called!“end!clipping”,!only!a!relatively!small!number!of!nucleotides!is!degraded.!The!second!phase!of!
processing!consists!of!extensive!resection,!which!is!carried!out!by!the!combined!actions!of!helicases!











(Schwertman! et! al.! 2016;! Hustedt! &! Durocher! 2017).! Once! the! template! has! been! invaded,! DNA!
synthesis! sets! in! to! copy! the! genetic! information! that! has! been! lost! due! to!DSB! formation.! This! is!
followed!by!dissolution!of!the!ensuing!structures,!which!results!either!in!a!crossover!between!the!sister!


































include! progressive! cerebellar! degeneration,! telangiectasia,! radiation! sensitivity,! premature! aging,!
immunodeficiency,! poor! growth,! gonadal! atrophy! and! a! marked! cancer! predisposition,! especially!




Figure, 5:, Homologous, recombination, (Modified!
from!Husted!&!Durocher!2017)!
The!critical!regulatory!node!to!decide!whether!DSBs!
are! repaired! through! NHEJ! or! HR! is! DNA! end!
resection.! This! in! turn! is! tightly! regulated! by! the!
rising! activity! of! CDKs! during! SOPhase.! CDK!
dependent! phosphorylation! of! NBS1! and! CtIP!
stimulates! end! resection! and! promotes! the!
recruitment! of! BRCA1.! BRCA1! then! counteracts!
53BP1! binding! to! the! break! site! and! further!
promotes! end! resection.! Long! range! resection! is!
achieved! through! the! combined! actions! of!
DNA2/BLM!and!EXO1,!which! is! also! stimulated!via!
CDK! dependent! phosphorylation! events.! BRCA1,!
BRCA2!and!PALB2!assist!the!replacement!of!RPA!on!
ssDNA! by! RAD51.! The! recombinase! RAD51! then!
performs! homology! search! and! strand! invasion,!
which! is! followed! by!DNA! synthesis.! The! resulting!
structures! can!be!dissolved!via!different!processes!









first! time.! RIDDLE! is! characterized! by! radiosensitivity,! immunodeficiency,! dysmorphic! features! and!
learning!difficulties.!Additional!symptoms!can!include!ataxia,!telangiectasia,!elevated!alphaOfetoprotein!
levels! and! pulmonary! failure.! These! symptoms! are! strikingly! similar! to! those! observed! in! ataxiaO
telangiectasia!patients!and!several!other!XCIND!syndromes!such!as!the!Nijmegen!breakage!syndrome!
(NBS)!and!radiosensitive!severe!combined!immunodeficiency!(RSOSCID).!In!addition,!cells!derived!from!
RIDDLE! patients! show! hypersensitivity! to! ionizing! radiation! and! exhibit! defective! DSB! repair! foci!
formation.!All!of!these!factors!indicated!that!RIDDLE!may!be!caused!by!mutations!in!an!unknown!DSB!
repair!protein!(Stewart,!Stankovic,!Byrd,!Wechsler,!Miller,!Huissoon,!Drayson,!West,!Elledge!&!A.!M.!R.!












DNA! replication! is! a! fundamental! requirement! for! cell! division! and! the! transmission! of! genetic!
information!to!the!next!generation,!making!it!essential!for!the!existence!of!all!forms!of!life!on!earth.!It!
is! thus!nor!surprising!that! the! fundamental!principles!of! replication!are!highly!conserved!among!all!
organisms!of!the!three!kingdoms!(Burgers!&!Kunkel!2017).!However,!there!are!considerable!differences!
in! replication! regulation! as! well! as! in! the! complexity! of! replication! factors! even! among! different!
eukaryotes.! Eukaryotic! cells! control! the! replication! of! their! genomes! by! precise! and! stringent!
regulatory!mechanisms! that! ensure! accurate! and! fast! genome! duplication! and! safeguard! genomic!
stability.!DNA!replication!is!tightly!monitored!and!closely!coupled!to!cell!cycle!progression.!This!ensures!
that!the!genome!is!replicated!exactly!once!per!cell!cycle,!and!that!the!replicative!process!is!completed!
before! the! cell! undergoes!mitosis.! Eukaryotic! genomes! can!be!of! considerable! size,! sometimes! far!
exceeding!a!billion!base!pairs!(bp),!and!are!generally!structured!into!multiple!chromosomes.!During!








genome! into! approximately! 5.000! units! of! simultaneously! firing! replication! clusters,! so! called!
replication!domains!that!harbour!up!to!30.000!origins! (Kelly!&!Brown!2000;!Branzei!&!Foiani!2010;!
RiveraOMulia! &! Gilbert! 2016;! Fragkos! et! al.! 2015).! In! certain! organisms! like! the! budding! yeast!
Saccharomyces(cerevisiae,!replication!origins!are!strictly!defined!by!consensus!sequences.!In!humans!
on!the!other!hand,!DNA!sequence!requirements! for! replication!origins!are!more!relaxed!and!origin!
determination! is! overall! based! on! DNA! secondary! structures,! chromatin! organization! and! specific!
epigenetic! marks! (Boulos! et! al.! 2015).! The! replicative! process! can! broadly! be! divided! into! three!
consecutive!stages:!Initiation,!elongation!and!termination.!The!following!subchapters!will!discuss!each!






binding! of! the! sixOsubunit! AAA+! ATPase! origin! recognition! complex! (ORC)! at! thousands! of! future!





























several! polymerase! accessory! factors! such! as! the! clamp! loader! replication! factor! C! (RFC)! and! the!



















































origins! will! eventually! meet! and! fuse! in! a! process! called! replication! termination.! Our! current!
understanding!of!the!eukaryotic!termination!process!is!still!incomplete.!Nonetheless,!several!general!









gets! disassembled! and! removed! from! the! DNA! (Dewar! et! al.! 2015).! Studies! in! budding! yeast! and!
Figure,6:,Elongation,(Snedeker!et!al.!2017)!
































surprisingly! poor! when! it! comes! to! discriminating! between! deoxyOribonucleotides! (dNTPs)! and!
ribonucleotides! (rNTPs).! This! leads! to! a! strikingly! high! rate!of! ribonucleotide!misincorporation! into!
























70%! of! the! human! genome.! Certain! repetitive! elements! can! be! inherently! difficult! to! replicate.!
Palindromic!sequence!repeats!may!for!example!form!secondary!structures!that!can!lead!to!fork!stalling!
and!breakage.!Replication! forks! also! tend! to! slow!at!GCOrich! repetitive! sequences,!which!has!been!
attributed!to!GOquadruplex!formation!at!these!sites.!It!is!thus!not!surprising!that!an!increasing!number!
of!diseases! such!as!Chorea!Huntington!and!Friedrich!Ataxia!are! correlated!with!genetic! changes! in!
repetitive! sequences! (Padeken! et! al.! 2015).! Another,! overlapping! class! of! difficult! to! replicate!
sequences! are! DNA! stretches! that! can! assume! nonOcanonical! BODNA! conformations.! This! includes!
regions! forming! triplex! DNA,! hairpins,! cruciform,! left! handed! ZODNA! and! the! above!mentioned! GO
quadruplexes!that!can!all!serve!as!roadblocks!for!replication!(Técher!et!al.!2017).!Importantly,!extended!
stretches! of! trinucleotide! repeats! that! assume! triplex! conformation! have! been! found! to! induce!

































and! cleaved! by! the! SLX4/MUS81! nuclease! complex.! Furthermore,! ATR! regulates! the! availability! of!
deoxyOribonucleotides!in!the!cell!by!promoting!an!increase!in!the!cellular!pool!of!the!ribonucleotide!
reductase! subunit! RRM2! (Blackford! &! Jackson! 2017).! ATR! and! the! closely! related! ATM! kinase!






is! achieved! by! transforming! an! active! replication! fork! into! a! fourOway! junction! through! partial!
reannealing! of! the! parental!DNA!duplex! and! simultaneous! displacement! and! annealing! of! the! two!
newly! synthesized! strands! into! a! fourth,! regressed! arm! (Neelsen!&! Lopes! 2015).! This! process! has!
recently! emerged! as! an! evolutionary! conserved! response! to! diverse! types! of! replication! stress,!
including!DNA!damaging!agents!(Zellweger!et!al.!2015;!which!is!part!of!this!thesis),!oncogene!activation!
(Neelsen!et!al.!2013)!and!difficult!to!replicate!DNA!sequences!(Follonier!et!al.!2013).!Despite!its!crucial!
role! in! genome! stability! maintenance,! the! precise! mechanistic! processes! and! signalling! cascades!
governing!the!reversal!and!subsequent!restart!of!replication!forks!are!only!partially!understood!(Quinet!







with!extensive! ssDNA!gaps! in!Xenopus! laevis!egg!extract!under! conditions!of!mild!genotoxic! stress!











directly! implicated! in! fork! slowing! and! reversal! in! human! cells! (Kile! et! al.! 2015).! The! human!















most! likely! arise! due! to! endogenous! obstacles! such! as! the! presence! of! repetitive! DNA! sequences!
(Follonier!et!al.!2013).!Considering!that!between!50!and!70%!of!the!human!genome!consist!of!repetitive!






absence! of! BRCA1/2,! stalled! forks! are! extensively! degraded! in! a! manner! that! depends! on! the!
endonuclease!activity!of!MRE11!(Schlacher!et!al.!2011;!Schlacher!et!al.!2012).!This!emerging!role!of!the!
BRCA!proteins!can!be! functionally!uncoupled! from!their!established!activities! in!HR!repair!and!was!







































treatments! in! avian! cells! (Xu! et! al.! 2017).! In! addition,! it! was! shown! that! 53BP1! protects! stalled!














the! central! DDR! factors! ATM,! RNF8,! RNF168! and! 53BP1! prevent! reversed! fork! accumulation! and!
subsequent!resection!at!difficult!to!replicate!sequences!throughout!the!human!genome.!Furthermore,!
I!have!shown!for!the!first!time!that!chromatin!is!regularly!assembled!on!the!regressed!arm!of!reversed!
replication! forks.! This! provides! an! attractive! target! for! the! E3! ligase! RNF168,! whose! role! in! fork!
protection!depends!on!its!ability!to!ubiquitinate!H2a!type!histones.!!
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Summary,,
Chromatin! ubiquitination! by! the! ubiquitin! ligase! RNF168! is! critical! to! regulate! the! DNA! damage!
response! (DDR).! DDR! deficiencies! lead! to! cancerOprone! syndromes,! but! whether! this! reflects! DNA!
repair!defects!is!still!elusive.!We!identified!key!factors!of!the!RNF168!pathway!as!essential!mediators!
of!efficient!DNA!replication!in!unperturbed!SOphase.!We!found!that!loss!of!RNF168!leads!to!reduced!
replication! fork! progression! and! to! reversed! fork! accumulation,! particularly! evident! at! repetitive!
sequences!stalling!replication.!Slow!fork!progression!depends!on!MRE11Odependent!degradation!of!
reversed! forks,! implicating!RNF168! in! reversed! fork!protection!and! restart.!Consistent!with! regular!




Keywords:! RNF168,! RNF8,! 53BP1,! ATM,! RIDDLE! syndrome,! ataxia! telangiectasia,! chromatin!
ubiquitination,!H2AK15Ub,!fork!reversal,!genome!stability!!
Introduction,,
Maintenance! of! genome! stability! is! an! active! process!within! the! cells,!which! copes!with! the! huge!



















as! the! cause! of! a! combined! disorder! called! RIDDLE! syndrome,! characterized! by! radiosensitivity,!
immunodeficiency,!microcephaly,!growth!retardation!and!cancer!predisposition!(Devgan!et!al.,!2011;!
Pietrucha!et!al.,!2017;!Stewart!et!al.,!2009).!Similarly,!mutations!in!the!apical!kinase!ATM!are!associated!
with! the! human! syndrome! Ataxia! telangiectasia,! which! combines! neurological! defects! with!
immunosuppression!and!elevated!cancer!risk.!Knockout!mouse!models!for!all!genes!in!this!pathway!
are! compatible! with! life,! but! display! different! combinations! of! phenotypes,! such! as! abnormal!
development,!infertility,! immunodeficiencies,!premature!aging!and/or!cancer!predisposition!(Specks!











BRCA2Odefective! tumors! (Ray! Chaudhuri! et! al.,! 2016;! Schlacher! et! al.,! 2011).! Differently! from!DSB!
processing!and!repair,!the!relevance!of!the!DSB!signaling!pathway!in!DNA!replication!has!not!yet!been!
thoroughly!investigated.!Large!53BP1!foci!in!G1Ophase!–!described!as!“53BP1!nuclear!bodies”!–!arise!
as! a! consequence!of! increased! replication! stress! in! the!previous! SOphase,! via!mitotic! processing!of!
residual! replication! intermediates! into!DSBs.! Recently,! Rad9/53BP1!was! shown! in! yeast! to! protect!
stalled!forks!from!degradation!(Villa!et!al.,!2018)!and!to!modulate!in!mammals!checkpoint!signaling!
and!stalled!fork!restart!(Her!et!al.,!2018;!Xu!et!al.,!2017).!However,!these!observations!were!made!upon!
exogenous! genotoxic! treatments,! and! a! potential! role! of! DSB! signaling! factors! in! unperturbed!
replication!has!not!been!investigated!to!date.!!







(Follonier!et!al.,!2013a).!This! transaction!was!proposed!to! limit! fork!progression!under!unfavorable!










fork! accumulation! at! difficultOtoOreplicate! sequences! and! their! processing!by!MRE11!nuclease.! This!
alternative!function!of!the!DDR!pathway!requires!RNF168Odependent!ubiquitination!of!H2A,!suggesting!
that! modifications! of! chromatin! –! which! we! found! regularly! assembled! on! the! regressed! arms! –!
promote! efficient! restart! of! endogenously! formed! reversed! forks! and! allow! continuous! fork!
progression.!This!novel!activity!of!the!DDR!pathway!may!provide!alternative!molecular!explanations!to!









FLAGORNF168! to! obtain! controlled! and! detectable! expression! of! RNF168,! we! noted! that! in! a!
subpopulation! of! cells! undergoing! DNA! replication! RNF168! partially! coOlocalizes! with! replication!
factories! marked! by! PCNA! foci! (Figure! 1A).! We! thus! investigated! a! possible! association! between!







close! proximity! to! PCNA,! while! the! UBD! does! not! show! any! significant! association! (Figure! 1D).!
Moreover,!to!determine!whether!RNF168/PCNA!interaction!occurs! in!a!specific!cell!cycle!phase,!we!
labelled!cells!with!5O!ethynylO2ÑOdeoxyuridine!(EdU)!to!clearly!mark!DNA!synthesis,!and!we!analyzed!












shRNF168! cells! show! a! marked! reduction! in! the! rate! of! EdU! incorporation! upon! RNF168!
downregulation!(doxycycline!addition),!indicating!impaired!DNA!synthesis!(Figures!2A,!S1A!and!S1B).!
We!next!used!the!DNA!fiber!spreading!assay!(Jackson!and!Pombo,!1998)!to!investigate!the!effect!of!









activation,!as! revealed!by!overall!nuclear! levels!of!H2A.X!phosphorylation! (gH2A.X,!Figure!2A,! right!
panel)! and!by! canonical!markers! of! checkpoint! activation! (KAP1O,! CHK1O! and!RPAOphosphorylation;!
Figure!2D).!To!further!exclude!that!this!reduction!in!DNA!synthesis!upon!RNF168!depletion!is!due!to!
increased! DNA! damage,! we! performed! a! DNA! comet! assay! comparing! RNF168Oproficient! with! O
deficient!cells.!The!two!cell!populations!did!not!differ!significantly,!while!cells!treated!with!the!DNA!



















test! the! hypothesis! that! replication! fork! remodeling! underlies! the! involvement! of! DDR! factors! in!
unperturbed!replication,!we!employed!an!established!EM!protocol!to!stabilize!and!visualize!in!vivo!the!
architecture! of! replication! intermediates,! in! presence! or! absence! of! RNF168.! Strikingly,! RNF168O
deficient! cells! reproducibly! showed! a! ~3Ofold! increased! accumulation! of! reversed! forks! during!
unperturbed! replication,! compared! to! RNF168Oproficient! cells! (Figures! 3A! and! S3AO! D;! Table! S1A),!
suggesting!that!RNF168!affects!the!dynamics!of!these!remodeled!replication!intermediates.!Reversed!
forks!are!transient!intermediates!and!their!accumulation!upon!genotoxic!treatments!depends!on!the!
balance! between! promoting! activities! –! such! as! the! central! recombinase! RAD51! or! the! dsDNA!




during! unperturbed! SOphase! (Figures! 3BOC! and! S3EOF),! while! depletion! of! ZRANB3! –! reportedly!
dispensable!for!endogenous!levels!of!fork!reversal!(Vujanovic!et!al.,!2017)!–!did!not!recapitulate!the!
same!effect!(Figures!3D!and!S3G).!Analogously,!PARP!inhibition!restored!efficient!fork!progression!in!
RNF168Odefective! cells! in! a! RECQ1Odependent! manner! (Figures! 3E! and! S3H).! Remarkably,! PARP!
inhibition! in! RIDDLE! cells! also! fully! rescued! efficient! fork! progression! to! the! levels! observed! upon!
RNF168!complementation!(Figures!3F!and!S3I).!Altogether,!these!results!indicate!that!replication!fork!
reversal! is!a!prerequisite!for!the!defective!fork!progression!observed!upon!RNF168!inactivation!and!
suggest! a! potential! role! for! RNF168! in! promoting! reversed! fork! restart.! Furthermore,! as! RAD51! is!
strictly! required! for! DSB! repair,! the! suppression! of! fork! slowing! upon! RAD51! inactivation! strongly!
argues! against! accumulation! of! endogenous! DSBs! as! the! underlying! mechanism! of! reduced! fork!









measured! by! EdU! incorporation! (Figure! S4A)! O! and! of! replication! fork! progression! (Figure! 4A).!

























treatments! (Figures! 4F! and! S4D).! This! gH2A.X! signal! is! specific,! since! cells! expressing! the! nonO
phosphorylatable!version!of!histone!H2A.X!(namely!H2A.XOS139A)!did!not!show!any!reactivity!with!the!
phosphoOspecific! antibody! (see! Figure! S4E).! Furthermore,! this! endogenous! gH2A.X! signal! is! largely!
reduced!upon!treatment!with!both!ATR!and!ATM!inhibitors! (Figure!4F).!Thus,!despite!undetectable!
global! DDR! activation! (Figure! 2AO2D),! local! ATR/ATMO!mediated! H2A.X! phosphorylation! detectably!
increases!during!cell!cycle!progression,!reaching!a!peak!in!late!SOphase!and!correlating!with!other!marks!
of! activation! of! the! DDR! cascade! (Figures! 1E! and! 1H).! Accordingly,! blocking! this! signaling! cascade!
downstream! by! RNF168! depletion! did! not! affect! global! H2A.X! phosphorylation,! but! induced! local!
accumulation!of!gH2A.X! in! these!endogenous! foci! (Figures!2A,!4F,!4G!and!S4F).!Similar!conclusions!













under! certain! genetic! perturbations,! which! mediates! the! chemosensitivity! of! BRCAOdefective! cells!
(Lemacon!et!al.,!2017;!Mijic!et!al.,!2017;!Ray!Chaudhuri!et!al.,!2016).!We!thus!tested!whether!MRE11O
dependent!degradation!is!also!implicated!in!the!defects!in!fork!progression!and!architecture!observed!
upon! interference! with! the! DDR! pathway.! Using!mirin! as! a! wellOcharacterized! inhibitor! of!MRE11!
nuclease! activity! at! replication! forks! (Schlacher! et! al.,! 2011),! we! found! that! MRE11! inhibition!














2017)!–!mirin! treatment! in!unperturbed!RNF8O,!RNF168O!or!53BP1Odefective!cells! invariably! lead! to!
further!marked!accumulation!of!reversed!forks!(Figures!5G!and!S5AOB;!Table!S1AOC).!Both!in!presence!









effect.! Impairing! this! degradation! would! prevent! fork! backtracking! and! promote! continued! fork!




unperturbed!conditions,! albeit!only! slightly!affecting! the! rate!of! fork!progression! (Thangavel!et! al.,!
2015;!Zellweger!et!al.,!2015).!The!marked!accumulation!of!reversed!forks!observed!by!inactivation!of!
MRE11!and!the!DDR!pathway!is!particularly!striking,!considering!that!these!cells!are!not!exposed!to!





K13/K15! promoted! by! RNF168! (Gatti! et! al.,! 2012;!Mattiroli! et! al.,! 2012),!which! is! required! for! the!
activation!of!the!downstream!signaling!cascade,!being!directly!recognized!by!53BP1!(FradetOTurcotte!
et!al.,!2013).!Hence,!we!asked!whether!this!histone!mark!is!also!essential!for!RNF168!function!in!DNA!
















only! intercalates! in! linker! DNA! between! nucleosomes,! this! analysis! reveals! the! nucleosomal!















factors! could! be! explained! by! a! role! of! these! proteins! in! replicating! genomic! regions! that! are!
intrinsically!difficult!to!replicate!and!are!thus!particularly!prone!to!fork!reversal.!Repetitive!sequences!
–!that!are!notably!abundant!in!the!human!genome!–!are!known!to!induce!replication!fork!slowing!(Neil!
et! al.,! 2017).! Recently,! expanded! GAA/TTC! sequences! –! which! are! linked! to! the! etiology! of! the!
neurodegenerative! syndrome! Friedreich’s! Ataxia! –! were! shown! to! undergo! frequent! fork! reversal!
under! unperturbed! conditions,! by! bidimensional! electrophoresis! (2D! gels)! and! EM! analysis! of!
chromatinized,!SV40Obased!plasmids!(Follonier!et!al.,!2013a)!(Follonier!and!Lopes,!2014).!Transfecting!
this!plasmid!system!in!U2OS!shRNF168!cells,!we!verified!that!control!plasmids!were!replicated!with!










in! Figure! 3A,! these! results! strongly! suggest! that! RNF168! is! required! to! prevent! reversed! fork!
accumulation! at! endogenous! difficultOtoOreplicate! regions,! presumably! by! promoting! effective!
reversed!fork!restart.! In! line!with!these!replication!problems,!we!observed!that!prolonged!(1!week)!
RNF168!depletion!in!U2OS!shRNF168!cells,!as!well!as!permanent!RNF168!inactivation!in!RIDDLE!cells,!
are! associated! with! increased! chromosome! abnormalities! in! mitosis,! mostly! visible! as! regions! of!
decondensed!chromatin!along!metaphase!chromatids!(Figure!7B!and!S7DOF).!The!effect!is!exacerbated!
when!DNA! replication! is! challenged!by! treating! cells!with! low!dose!of!aphidicolin! (Aph,!Figure!7C).!














We!now!show! that! these! factors!are! required! for!efficient! replication! fork!progression!even! in! the!
absence!of!exogenous!stress!and!detectable!DNA!breakage!or!DSB!signaling,!identifying!a!new!crucial!
role!for!this!pathway,!in!addition!to!its!established!role!in!the!DSB!response.!Four!important!lines!of!
evidence! support! a! specific! role! for! the! RNF168Oassociated! DDR! pathway! during! unperturbed!
replication,!independently!of!DSB!formation:!1)!RNF168!coOlocalizes!and!physically!interacts!with!PCNA!
at!a!subset!of!replication!factories!in!unperturbed!conditions,!which!are!not!associated!with!detectable!
DDR!activation!or!physical! evidence!of!DNA!breaks;! 2)! the! replication! function!of!RNF168! requires!










Chaudhuri!et!al.,!2016;!Schlacher!et!al.,!2012).!Several!groups! reported! that! this! clinically! relevant,!





to! protect! forks! reversed! upon! Topoisomerase! I! inhibition! from! degradation! (Menin! et! al.,! 2018).!
Remarkably,! using! multiple! genetic! tools! to! interfere! with! replication! fork! remodeling! (i.e.! PARP!
inhibition! and! RAD51,! SMARCAL1! or! RECQ1! depletion),! we! found! that! also! the! surprising! defects!
observed!during!unperturbed!replication!upon!inactivation!of!RNF168!strictly!depend!on!replication!




An! important! implication! of! our! EM! observations! is! that,! even! during! unperturbed! SOphase,! a!
surprisingly! high! number! of! replication! forks! undergo! reversal,! imposing! efficient! fork! restart!
mechanisms!to!prevent!massive!accumulation!of!reversed!forks.!This!is!consistent!with!the!effects!on!
fork! progression! and! architecture! reported! for! PARG! inactivation,! which! is! expected! to! shift! the!
equilibrium!of!stalled!forks!towards!a!reversed!state!and!result!in!their!defective!restart!(Ray!Chaudhuri!
et!al.,!2015).!Several!chromosomal!regions!have!been!identified!as!“difficultOtoOreplicate”,!be!it!because!
of! their! repetitive! nature,! their! propensity! to! form! secondary! structures! and/or! their! active!
transcription!(Glover!et!al.,!2017;!Neil!et!al.,!2017).!DifficultOtoOreplicate!regions!tend!to!be!replicated!




progression! upon! inactivation! of! the! DDR! pathway! during! the! labelling! time! of! a! standard! fiber!
spreading! experiment.! It! is! likely! that! a! large! fraction! of! replication! forks! frequently! undergoes!
transient! remodeling! and! requires! an! active! DDR! pathway! to! efficiently! drive! fork! protection! and!
restart.! In! that! respect,! RNF168! activation! may! consistently! occur! at! replication! forks,! but! the!




stranded!end!during! fork! remodeling! implies!an! intrinsic! risk!of!DDR!activation,!posing!very! similar!
issues!to!those!extensively!characterized!at!telomeres!(Maciejowski!and!de!Lange,!2017).!However,!


















may! limit! access! to! nucleases.! This! may! be! achieved! by! direct! protection! of! the! end! and/or! by!
promoting! an! alternative! pathway! of! reversed! fork! restart! –! e.g.! via! RECQ1Odependent! branch!
migration!–!which!does!not!implicate!DNA!end!resection.!Alternatively!and!in!analogy!with!its!role!in!
HROmediated!DSB!repair!(Smeenk!and!Mailand,!2016),!RNF168O!dependent!chromatin!ubiquitination!
may! finely! control! regressed! arm! resection! and! promote! RAD51Omediated! fork! protection! and!
restoration!mechanisms.! Indeed,!besides! the!wellOestablished!competition!of!53BP1!and!BRCA1! for!
DSB!repair!mechanism!(Bunting!et!al.,!2010),!our!data!highlight!the!importance!of!ubiquitinO!dependent!










replication! forks,! as! this! would! increase! the! risk! of! unscheduled! nucleolytic! processing! and!
chromosomal! rearrangements.! In! fact,! the! evidence! that! nucleosomes! are! deposited! on! regressed!










proliferation! and! on! patientOspecific! responses! to! chemotherapeutic! treatments! interfering! with!
replication.!!
Overall,!this!work!directly!involves!key!DDR!factors!in!the!molecular!mechanisms!promoting!efficient!
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ubiquitin! (Yau!&!Rape!2016).!Thus,!proteasome! inhibitors!can!be!used!to! interfere!with!normal!Ub!
signalling!in!the!cell.!To!get!an!impression!whether!ubiquitin!signalling!plays!a!role!during!unperturbed!
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a. SCR 48h siUB 16h siUb 24h siUb 36h siUb 48h
5.1.2.! Ubiquitin,depletion,
Proteasome! inhibition! is! a! very! indirect! way! to! study! the! function! of! Ub! signalling! in! replication.!
Furthermore,!proteasome!inhibitors!are!toxic!agents!that!may!cause!unanticipated!problems!in!cells!






































Next,! I!performed!DNA!fiber!spreading!experiments!to!assess!at!single!molecule! level! the!potential!
effect!of!Ub!depletion!on!fork!progression!(Figure!P3).!These!two!conditions!were!chosen!because!they!

























































which! is! an! inherent!problem!with! transient! knockdown! systems.! To!overcome! this! shortcoming,! I!
employed!a!previously!established!U2OS!based!RNAi!system!for!the!tetracyclineOinducible!knock!down!
of!ubiquitin! (M.!Xu!et!al.!2009).!This!cell! line! (U2OS(shUb),! stably!expresses!multiple!copies!of! two!
tetracyclineOinducible!shRNAs!that!target!all!four!Ub!precursors!in!the!human!genome!(UBC,!UBA52,!


























treatment.! Second,! just! as! in! the! transient! knockdown! system,! Ub! depletion! clearly! impairs! DNA!
replication.!Replication!problems!are!already!apparent!after!24h!of!tetracycline!treatment.!At!this!point!
the!EdU!intensity!of!the!mid!SOphase!population!is!shifted!downwards!and!cells!start!to!accumulate!in!
G2.! After! 36h! of! Tet! exposure,!most! SOphase! cells! show! severely! reduced! EdU! incorporation! rates!
combined!with!an!intermediate!DNA!content,!indicating!that!they!have!undergone!replicative!arrest.!
This!acute!impairment!of!DNA!synthesis!is!accompanied!by!a!marked!accumulation!of!cells!in!the!G1O!









chain! is!not!possible!with! these!mutant!polypeptides.!This!allows! to!evaluate! if! the!presence!of!an!
individual!Ub!linkage!type!is!necessary!for!a!distinct!cellular!process!such!as!DNA!replication.!However,!
the!functional!consequences!of!expressing!K/R!mutants!in!human!cells!can!only!be!appreciated!if!the!
endogenous! Ub! is! depleted! at! the! same! time,! which! constitutes! a! replacement! experiment.! To!
determine!if!specific!Ub!chains!are!required!for!efficient!replication,!I!aimed!to!perform!replacement!













expression! levels! of! FLAGOtagged! WT! Ub! were! monitored! by! EDU/DAPI/Flag! FACS! (Figure! P6).!


































possible! replication!effects!occurring!upon!Ub!replacement! in! these!cellular! systems,!another!FACS!
based!timeOcourse!experiment!was!performed.!DAPI!content,!EdU!incorporation!and!the!levels!of!Ub!


























rescued! under! these! conditions,! whereas! replication! is! still! severely! impaired! in!U2OS( K63R! cells.!
Figure,P7:,Ub,K63,is,required,to,ensure,normal,rates,of,DNA,synthesis,,
a.,FACS!analysis!of!U2OS(Ub(WT!cells!stained!for!EdU,!DAPI!and!Ub!conjugates!(FK2)!at!different!timeOpoints!of!tetracycline!







albeit! the! rescue! in!U2OS!Ub!WT! cells! is! less! pronounced.! This! experiment! demonstrates! that! the!
presence!of!Ub!K63! is! required! to!ensure!efficient! rates!of!DNA! synthesis! in!unperturbed!SOphase.!
Monitoring! EdU! incorporation! rates! by! FACS! can! however! not! reveal! whether! this! impairment! of!
replication! is! brought! about! by! reduced! origin! firing,! impaired! replication! fork! progression! or! a!
combination!of!both.!
To!find!out!if!the!absence!of!Ub!K63!has!a!direct!effect!on!the!speed!of!individual!replication!forks,!a!






































The!marked! replication!defects! in!RNF168!depleted! cells! discussed! in! previous! chapters! raised! the!
question! if! cell! survival! or! proliferation!may! also! be! affected! in! the! absence! of! this! E3! ligase.! To!
investigate!this,!I!performed!a!clonogenic!assay!and!a!growth!curve!experiment!(Figure!P9).!While!the!
former!assay!measures!cell!survival,!the!latter!reflects!a!combination!of!cell!survival!and!proliferation!












































U2OS shRNF168 + Dox (1  μg/ml) 




































previous! CTB! experiment! was! employed,! checking! for! their! effect! on! EdU! incorporation! rates! in!
presence!and!absence!of!RNF168!(Figure!P11).!In!addition!to!the!agents!tested!in!the!CTB!experiment,!
the! effects! of! hydroxyurea! (HU)! and! trimethylpsoralen! (TMP)!were! assessed! as!well.! TMP! induces!
interstrand! crosslinks! upon! photo! activation! by! UVOA! (Cech! &! Pardue! 1977)! and! a! paper! in! 2015!



































































Interestingly,! treatment!with! these! two! genotoxic! agents! led! to! very! distinct! outcomes! in! RNF168!
depleted!cells.!APH!had!a!clear!additive!effect,!further!slowing!the!already!impaired!fork!progression!




prompted! the! question! if! similar! discrepancies! could! be! observed! in! terms! of! replication! fork!
architecture.!To!investigate!the!effect!of!these!genotoxic!treatments!on!the!frequency!of!reversed!forks!
upon! RNF168! depletion,! I! performed! an! electron! microscopy! (EM)! experiment! under! the! same!
treatment!conditions!used!in!the!fiber!experiment!(Figure!P13).!
! !
Figure, P12:, Distinct, effects, of, genotoxic, agents, on, fork,
speed,in,RNF168,depleted,cells.,








































not!have!an!additive!effect!but! led!to! the!same!frequency!of! reversed! forks!as!observed!upon!CPT!
treatment!alone.!APH!treatment!led!to!a!32%!frequency!of!reversed!forks!in!RNF168!depleted!cells.!
The! previously! reported! fork! reversal! frequency! upon! APH! treatment! in! U2OS! cells! is! only! 23%!
(Zellweger!et!al.!2015),!suggesting!that!APH!could!have!an!additive!effect!on!fork!reversal!in!cells!lacking!
RNF168.! It! is!possible! that!APH!and!CPT!treatment!cause!distinct!architectural! features!of! reversed!
forks!and/or!the!recruitment!of!separate!sets!of!signalling!and!processing!factors,!which!may!underlie!






we!showed!that!both!ATM!and!RNF8!are!epistatic! to!RNF168! in!protecting!stalled!replication! forks!
during!unperturbed!SOphase.!We!therefore!expected!that!MDC1!could!also!be!epistatic!to!RNF168!in!
this!context.!To!test!if!the!loss!of!MDC1!has!an!impact!on!DNA!replication!and!whether!it!is!epistatic!to!


































the! DDR! mediated! fork! protection! pathway! we! investigated! in! Schmid! et! al.! 2018.! To! test! this!









RNF168!depleted! (siRNF168,!U2OS!WT),!MDC1!KO! (siLUC,!MDC1!KO)!and!RNF168/MDC1!coOdepleted!cells! (siRNF168,!















Knockdown!of!Ku70/80! led! to!a! significant! increase! in! replication! fork! speed!both! in!presence!and!





not!be!able! to!effectively!keep! forks! in!a! reversed!state,!which!could!explain! the!unrestrained! fork!























Figure, P16:, Knock, down, of, Ku70/80, has, no,
detectable,effect,on,fork,reversal,frequency,
a., EM! experiment! investigating! the! effect! of! CPT!
treatment! (25nM)! on! the! frequency! of! reversed!
forks! in!control! (siLUC)!and!Ku70/80!depleted!cells!
(siKu70/80).! The!numbers! in!brackets! indicate! the!
total! of! analyzed! molecules! for! each! sample.! The!
frequency! of! reversed! forks! is! shown! above! each!

























Interestingly,! inhibiting! DNAOPKc! has! a! significantly! stronger! effect! on! fork! speed! than! RNF168!
depletion.!However,!upon!knockdown!of!RNF168,!DNAOPKc!inhibition!caused!a!dramatic! increase!in!






























a., Statistical! analysis! of! IdU! track! lengths! from! a! DNA! fiber! spreading!
experiment! in! U2OS! shRNF168! cells.! The! presented! samples! include!
control!cells! (NT,!O!Dox),!cells!treated!with!1µM!of!the!DNAOPKc!inhibitor!







The! finding! that! depletion! of! the! free! ubiquitin! pool! has! a! severe! impact! on! DNA! replication! in!
unperturbed!SOphase!(see!Figures!P1OP5)!is!not!entirely!unexpected.!Ub!signaling!has!previously!been!
implicated!in!promoting!cell!cycle!progression!through!SOphase!(Nakayama!&!Nakayama!2006),!and!in!
regulating! origin! licensing! (Havens!&!Walter! 2011)! and! replication! termination! (Maric! et! al.! 2014;!
Moreno!et!al.!2014).!Moreover,!impairing!ubiquitination!is!known!to!abolish!the!turnover!of!shortOlived!
proteins!in!the!cell!and!leads!to!an!accumulation!of!misfolded!proteins!within!the!lumen!and!membrane!
of! the! endoplasmatic! reticulum! (Hyer! et! al.! 2018).! Such! proteotoxic! stress! triggers! a! downstream!
signaling!cascade!called!the!unfolded!protein!response!(UPR)!which!can!promote!cell!cycle!arrest!and!











assemble! K63! chains! on! chromatin! (Thorslund! et! al.! 2015).! However,! K63! linked! polyOubiquitin!
constitutes! the!second!most!abundant!chain!type! in!human!cells,! regulating!a!plethora!of!different!
cellular!mechanisms!ranging! from!DNA!repair! to!cytokine!signaling! (Chen!&!Sun!2009).! It! therefore!
seems! unlikely! that! the! observed! replication! problems! in! U2OS! K63R! cells! are! solely! the! result! of!
impaired! RNF8! dependent! fork! protection.! A! more! plausible! explanation! is! that! they! reflect! the!
deregulation!of!several!K63Odependent!signaling!pathways.!To!address!this!question!one!could!deplete!
RNF8!and/or!RNF168!in!cells!lacking!K63!chains!and!check!for!epistatic!effects!on!fork!progression!by!














thereby! evaluating! the! severity! of! DNA! lesions! after! full! ubiquitin! replacement.! This! would! allow!
drawing!solid!conclusions!about!the!role!of!K63!chains!in!unperturbed!replication.!
Overall!the!data!on!the!function!of!Ub!chains!in!DNA!replication!presented!in!this!manuscript!is!not!yet!
conclusive.! The! cellular! Ub! replacement! systems! used! in! my! experiments! have! considerable!
shortcomings!and!the!ubiquitin!chain!project!was!abandoned!at!an!early!stage!to!focus!on!the!role!of!
the!Ub!dependent!DNA!damage!response!in!unperturbed!replication.!
Histone, ubiquitination, by, the, DNA, damage, response, is, required, for, efficient, DNA,
replication,in,unperturbed,SXphase,(Schmid,et,al.),















RNF168! localizes! to! active! replication! factories! during! unperturbed! replication! in! a! UbOdependent!
manner,!which!is!in!line!with!published!proteomics!results!(Alabert!et!al.!2014).!However,!it!remains!




Schmid! et! al.).! Analysis! of! sister! fork! symmetry! showed! that! this! slowdown! is! at! least! partially!
attributable!to!an! increased!frequency!of! replication! fork!stalling.!Median! fork!speed!upon!RNF168!
depletion! is! reduced! by!more! than! 30%,!which! is! comparable! to! the! effect! of! low! dose! genotoxic!




depletion.! Combined! with! the! negative! data! described! above,! these! results! imply! that! H2AX!






several! of! the! clinical! symptoms! observed! in! RIDDLE! patients! (Stewart,! Stankovic,! Byrd,!Wechsler,!
Miller,!Huissoon,!Drayson,!West,!Elledge!&!!a!M.!R.!Taylor!2007;!Pietrucha!et!al.!2017)!may!be!related!
to!replication!defects!caused!by!RNF168!deficiency.!
Interestingly,! we! found! that! besides! a! slowdown! in! fork! progression,! RNF168! depletion! also!





the!PARP! inhibitor!olaparib!–!previously!reported!to! impair! reversed!fork!accumulation! (Berti!et!al.!
2013)! O! rescued! fork! speed! in! a! RECQ1! dependent! manner.! These! results! suggest! that! slow! fork!




ZRANB3! in! RNF168! deficient! cells!may! potentially! reflect! distinct! functions! of! these! two! annealing!





ATM! in! U2OS! cells! causes! a! significant! decrease! in! replication! fork! speed! and! an! approximately!
threefold!increase!in!the!frequency!of!reversed!replication!forks!(see!Figure!4!in!Schmid!et!al.).!This!
slowdown! in! fork! progression! was! not! exacerbated! when! coOdepleting! RNF168! in! the! same! cells,!
suggesting! that! these!DDR! factors! are! epistatic! in! the! context!of!DNA! replication.! Interestingly,!AT!
patient! cells! also! show! reduced! replication! fork! speed,! opening! the! possibility! that! some! of! the!


















The! surprising! finding,! that! Mre11! inhibition! partially! rescues! fork! speed! while! at! the! same! time!
exacerbating!the!accumulation!of!reversed!forks!in!DDR!deficient!cells!(see!Figure!5!in!Schmid!et!al.)!is!







deduce! how! exactly!Mre11! activity! leads! to! slow! fork! progression! in! DDR! defective! cells,! but! two!
possible!mechanisms! come! to!mind.! The! first! possibility! is! that!Mre11! initiates!mid! to! long! range!
resection!of! newly! synthesized!DNA! resulting! in! extensive!backtracking!of! replication! forks.! Such!a!
process! can! be! observed! in! BRCA2! depleted! cells! upon! prolonged! fork! stalling! by! HU,! where! the!
resection!depends!on!the!joint!activity!of!Mre11!and!EXO1!(Schlacher!et!al.!2011;!Ray!Chaudhuri!et!al.!
2016;!Mijic!et!al.!2017;!Lemaçon!et!al.!2017).!The!second!possible!mechanism!is!that!Mre11!dependent!
degradation! of! reversed! forks! may! produce! a! DNA! intermediate! that! would! require! extensive!
processing!before!replication!can!be!resumed!efficiently!at!the!same!fork.!Such!a!mechanism!can!be!









H2A! and! H2AX! (Mattiroli! et! al.! 2012),! we! found! that! the! same! activity! is! also! required! during!
unperturbed!DNA!replication!(see!Figure!6!in!Schmid!et!al.).!This!could!imply!that!–!reminiscent!of!the!
classical!DDR!pathwayO!RNF168!ubiquitinates!histone!variants!H2A!on!reversed!replication!forks!and!








structural! similarity! between! such! intermediates! and! DNA! doubleOstrand! breaks.! Both! structure!
present! unshielded! DNA! ends,! contain! nucleosomes! and! are! protected! and! processed! by! an!
overlapping! set! of! proteins.!One!may! even! assume! that! it!would! be! difficult! for! the! cell! to! clearly!











































were! low! dose! ETP! and! HU.!Measuring! EdU! intensities! in! SOphase! cells! represents! a! rather! crude!




















shown!to!mediate! fork!protection!when!cells!are!subjected!to! low!doses!of!CPT! (Mijic!et!al.!2017).!











cells! (Figure! P14a).! These! observations! open! the! possibility! that! MDC1! is! not! required! for! the!
recruitment!of!RNF168!to!reversed!replication!forks!but!is!instead!involved!in!an!alternative!pathway!
ensuring! efficient! replication! under! unperturbed! conditions.! To! test! this! hypothesis! one! should!
perform! a! proximity! ligation! assay! between! RNF168! and! PCNA! in! control! and! MDC1! null! cells.!
Unfortunately,!time!restrictions!did!not!allow!me!to!perform!such!an!experiment.! Interestingly,!the!
mild! replication! defects! in! MDC1! KO! cells! that! are! exacerbated! by! coOdepletion! of! RNF168,! are!










chapters.!Surprisingly,!we! found! that!knockdown!of! the!KuOcomplex! led! to!a! significant! increase!of!
replication!fork!speed!in!control!cells!and!rescued!fork!speed!when!coOdepleted!with!RNF168!(Figure!
P15).!This!indicates!that!the!Ku!complex!restrains!fork!progression!both!in!presence!and!absence!of!




render! replication! forks! unable! to! assume! a! sufficiently! stable! reversed! conformation,! one! could!
indeed! expect! faster! fork! progression! under! control! conditions! as! well! as! strongly! reduced! fork!








progression! as! the! knockdown! of! Ku70/80! (Figure! P17).! Perplexingly,! inhibiting! DNAOPKc! led! to! a!
significant! reduction! in! the! rate! of! fork! progression! in! control! cells! while! dramatically! increasing!


























































tetracyclineOfree! FBS! (Biowest! S181T)! as! well! as! 100! U/ml! penicillin,! 100! µg/ml! streptomycin! and!













EdU,! washed! with! PBS,! fixed! in! 4%! buffered! paraformaldehyde,! washed! three! time! with! PBS,!
permeabilized!for!10!min!at!room!temperature!in!0.3%!Triton!XO100!(SigmaOAldrich)!in!PBS!and!washed!




were!washed! three! times!with!PBS! containing!0.1%!TweenO20! (SigmaOAldrich).! SecondaryOantibody!
incubations!were!performed!at!room!temperature!for!1!hour.!After!one!wash!with!PBS!containing!0.1%!
TweenO20! and! one!with! PBS,! coverslips!were! incubated! for! 10!min!with! PBS! containing! DAPI! (0.5!


















PCNA! antibody! and! in! situ! proximity! ligation!was! performed!using! a!Duolink!Detection! Kit! (SigmaO
Aldrich).!!
Quantitative,imageXbased,microscopy,(QIBC),,
Automated! multichannel! wideOfield! microscopy! for! QIBC! was! performed! as! described! previously!
(Altmeyer!et!al.,!2013;!Toledo!et!al.,!2013)!on!an!Olympus!ScanR!Screening!System!equipped!with!wideO
field! optics,! a! 20x,! 0.75ONA! (UPLSAPO! 20x),! an! inverted! motorized! Olympus! IX83! microscope,! a!
motorized!stage,!IROlaser!hardware!autofocus,!a!fast!emission!filter!wheel!with!singleOband!emission!
filters,! and! a! 12Obit! digital!monochrome!Hamamatsu!ORCAOFLASH!4.0!V2! sCMOS! camera! (dynamic!
range!4,000:1,!2,048!3!2,948!pixel!of!size!6.5!3!6.5!mm,!12Obit!dynamics).!Images!were!acquired!in!an!





the!DAPI! signal,! and! foci! segmentation!was!performed!using!an! integrated! spotOdetection!module.!
Fluorescence!intensities!were!quantified!and!are!depicted!as!arbitrary!units.!These!values!were!then!
exported! and!analysed!with! Spotfire!data! visualization! software! (TIBCO,! version!5.0.0).!Within!one!
experiment,!similar!cell!numbers!were!compared!for!the!different!conditions.!To!visualize!discrete!data!
in! scatterplots! (e.g.,! foci! numbers),! mild! jittering! (random! displacement! of! data! points! along! the!
discrete!data!axes)!was!applied!to!demerge!overlapping!data!points.!Representative!scatterplots!and!





nM;! 5’OCGUACGCGGAAUACUUCGAUUdTdTO3’);siRNF168! (72h! 40! nM:! 5’O
CGUGGAACUGUGGACGAUAAUUCAAdTdTO3’);! siRAD51! (24h! 40! nM:! 5’O
GACUGCCAGGAUAAAGCUUdTdTO3’);siRECQ1! (72h! 40! nM:! SMART! pool! against! human! RECQ1,!
NM_032941,!Dharmacon);!siUb!(12/16/20/24/36/48h!40!nM:!5ÑOACACCAUUGAGAAUGUCdTdTO3Ñ!and!






trypsinization!and!subsequently! fixed! for!10!min! in!4%! formaldehyde/PBS.!Cells!were! then!washed!
twice!and!blocked!over!night!at!4°C!with!1%!BSA/PBS,!pH!7.4.!They!were!permeabilized!the!next!day!
with! 0.5%! saponin/1%!BSA/PBS,! and! stained!with! the! respective! primary! antibody! diluted! in! 0.5%!

















fixed! in! 3:1!methanol/acetic! acid,! and! stored! at! 4°C! overnight! The!DNA! fibers!were! denatured! by!
incubating!them!in!2.5!M!HCl!for!1h!at!RT,!washed!five!times!with!PBS!and!blocked!with!2%!BSA!in!PBST!
(PBS!and!Tween!20)!for!40!min!at!RT.!The!newly!replicated!CldU!and!IdU!tracks!were!stained!for!2.5h!





















at!1:30’000! in!TrisOEDTA! (10!mM!TrisOHCl!pH!7.5,!1!mM!EDTA)! for!30!min! in!dark.!Microscopy!was!
performed!on!a!Leica!DM6!B!upright!digital! research!microscope!equipped!with!a!DFC360!FX!Leica!









μM! NOEthylmaleimide! [NEM]).! Extracts! for! all! other! immunoblot! experiments! were! prepared! in!
Laemmli!sample!buffer!(4%!SDS,!20%!glycerol,!and!120!mM!TrisOHCl,!pH!6.8).!40!μg!total!protein!from!
cell!isolates!were!loaded!onto!4O20%!MiniOPROTEAN®!TGXTM!Precast!Protein!Gels!(BIO!RAD).!Proteins!
were! separated!by! electrophoresis! at! 16!mA! followed!by! transferring! the!proteins! to! ImmobilonOP!
membranes!(Thermo!Fisher!Scientific)!for!1h!at!350mA!(4°C)!in!transfer!buffer!(25!mM!Tris!and!192!
mM! glycine)! containing! 10%! methanol.! Before! addition! of! primary! antibodies,! membranes! were!
blocked!for!1h!in!TBS!containing!0.1%!Tween!20!and!5%!milk.!!
Enrichment,for,mitochondrial,DNA,
Mitochondrial! DNA! was! enriched! using! a! mitochondrial! DNA! Isolation! Kit! (Abnova! Cat#! KA0895)!
according!to!the!manufacturers! instructions.!Subsequently!the!DNA!was!purified!and!concentrated,!






psoralen! crossO! linking! of! the! DNA! was! performed! by! exposing! twice! the! living! cells! to! 4,5’,8O
trimethylpsoralen!at!a!final!concentration!of!10!μg/ml!followed!by!short!(3!min)!irradiation!pulses!with!

























chilled! immediately! after!on! ice.! After! this!denaturation! step! the!mixture!was! spread!by! the!BAC!
method!onto!carbonO!coated!400Omesh!magnetic!nickel!grids.!After!the!spreading!procedure,!the!DNA!
was!platinum!coated!by!platinumOcarbon!rotary!shadowing!(High!Vacuum!Evaporator!MED!020;!BalO
Tec)! to!make! it! electron! dense.! The! grids!were! scanned! using! a! transmission! electron!microscope!
















digital! research!microscope!equipped!with!a!DFC360!FX!Leica! camera.! Images!were!analyzed!using!




doxycycline! to! the!growth!media! (1!μg/ml! final!concentration,!96h)!were! transfected!with!an!SV40!
based! plasmid! containing! 90! TTC! repeats! using! jetPRIME®! (Polyplus! transfection).! The! cells! were!


































Signaling!Technology),!CHK1!mouse! (scO8408;!Santa!Cruz!Biotechnology),!KAP1!pS824! rabbit! (A300O
767A;! Bethyl! Laboratories),! KAP1! rabbit! (A300O274A;! Bethyl! Laboratories),! phosphoORPA32! (S4/S8)!
rabbit!(A300O245A;!Bethyl!Laboratories),!RPA32!rabbit!(A300O244A;!Bethyl!Laboratories),!RAD51!(HO92)!
rabbit!(scO8349;!Santa!Cruz!Biotechnology),!53BP1!rabbit!(ab36823!Abcam)!RNF168!rabbit!(generated!
by! R.! Freire),! RNF8! rabbit! (generated! by! R.! Freire).! RECQ1! rabbit! (ABC1428,! SigmaOAldrich,! kindly!
provided!by!A.!Vindigni),!total!ubiquitin!mouse!(P4D1,!scO8017;!Santa!Cruz!Biotechnology).!Secondary!
antibodies! used! for! western! blotting! were! antiOrabbit! and! antiOmouse! ECL! (GE! Healthcare).! The!
following!primary!and!secondary!antibodies!were!used!for!FACS!stainings:!mouse!anti–#H2AX!(05O636;!
EMD!Millipore),!rabbit!polyclonal!antiOFLAG!(F7425,!SigmaOAldrich),!FK2!mouse!monoclonal!antibody!









acids! 300O571)! were! cloned! into! pET28a! (Novagen)! vector! for! expression! in! Escherichia! coli.!












Twelve! 10! cm!dishes!were! seeded!with! 3! x! 105!cells! each.! The! number! of! cells! per! dish!was! then!
measured!in!triplicates!every!24!hours!using!an!automated!cell!counter.!The!total!of!12!dishes!allowed!













hours! at! 37°C! to! give! the! cells! time! to!metabolize! the! resazurin.! After! that! the! fluorescence! was!






















along! the! discrete! data! axes)! was! applied! to! demerge! overlapping! data! points.! Representative!













































































































































































































































































































































































































slowing,% ssDNA% accumulation% and% fork% reversal% upon% genotoxic% treatments% is% not% necessarily%
coupled%to%detectable%ATR%or%ATM%activation.%
My%personal%contribution%to%this%manuscript%consist%of% the%FACS%analysis%presented% in% figure%4D%
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Introduction
One of the most widely used approaches in cancer chemother-
apy is to kill cancer cells or arrest their rapid proliferation by 
targeting DNA replication. As genome duplication is essential 
for every cell division, replication interference is inherently 
more toxic to rapidly proliferating cancer cells than to untrans-
formed, mostly quiescent somatic cells. Different strategies for 
replication interference have been explored and are often 
combined in chemotherapeutic regimens. A first class of drugs 
target DNA topoisomerases, essential factors to release torsional 
stress accumulating during replication (Pommier, 2013 and 
references therein). Topoisomerase I (Top1) inhibitors of the class 
of camptothecin (CPT) are commonly used to treat ovarian, lung, 
and colorectal cancer and act by trapping the enzyme on the 
DNA after strand cleavage. The same principle of “interfacial 
inhibition” applies to Topoisomerase II (Top2) inhibitors, such 
as etoposide (ETP) and doxorubicin (DOX), both potent che-
motherapeutic drugs commonly used to treat various cancers 
(Pommier, 2013 and references therein). ETP is the most selec-
tive Top2 inhibitor available in the clinics and, at clinically 
relevant doses, mostly induces single-strand breaks, by asym-
metrical trapping of Top2 homodimers (Kerrigan et al., 1987). 
Conversely, DOX intercalates in the DNA molecule and in-
duces “concerted” trapping of Top2 complexes, mostly leading 
to double-strand breaks (DSBs; Zwelling et al., 1981). A sec-
ond frequent strategy for replication interference in cancer 
chemotherapy makes use of antimetabolites to block nucleotide bio-
synthesis or DNA polymerization, as for the ribonucleotide 
reductase inhibitor hydroxyurea (HU) or the DNA polymerase 
inhibitor aphidicolin (APH). HU is commonly used to treat 
hematological malignancies and has been extensively used in 
basic research to investigate the consequences of replication 
fork stalling (Madaan et al., 2012). Similarly, APH has been 
used to study chromosome fragility during replication (Arlt 
et al., 2012) but has also been considered to potentiate specific 
Replication fork reversal protects forks from break-age after poisoning of Topoisomerase 1. We here investigated fork progression and chromosomal 
breakage in human cells in response to a panel of sub-
lethal genotoxic treatments, using other topoisomerase 
poisons, DNA synthesis inhibitors, interstrand cross-linking 
inducers, and base-damaging agents. We used electron 
microscopy to visualize fork architecture under these 
conditions and analyzed the association of specific 
molecular features with checkpoint activation. Our data 
identify replication fork uncoupling and reversal as global 
responses to genotoxic treatments. Both events are fre-
quent even after mild treatments that do not affect fork in-
tegrity, nor activate checkpoints. Fork reversal was found 
to be dependent on the central homologous recombina-
tion factor RAD51, which is consistently present at repli-
cation forks independently of their breakage, and to be 
antagonized by poly (ADP-ribose) polymerase/RECQ1-
regulated restart. Our work establishes remodeling of un-
coupled forks as a pivotal RAD51-regulated response to 
genotoxic stress in human cells and as a promising target 
to potentiate cancer chemotherapy.
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improve the anticancer response, and to avoid resistance or 
relapse of specific cancer types.
Replication fork reversal—i.e., the conversion of a repli-
cation fork into a four-way junction by reannealing of parental 
strands and coordinated annealing of nascent strands—was ini-
tially proposed by (Higgins et al., 1976), as a model for damage 
bypass during replication in human cells. Albeit conceptually at-
tractive, the model has long remained unsubstantiated, and fork 
reversal has been rather associated with unscheduled transac-
tions at unprotected replication forks in specific yeast mutants 
(Lopes et al., 2001, 2006; Sogo et al., 2002; Bermejo et al., 
2011). More recently, however, fork reversal was reported as 
a strikingly frequent event upon mild Top1 poisoning in wild-
type yeast cells, as well as mouse and human cells, and Xenopus 
laevis egg extracts (Ray Chaudhuri et al., 2012). Genetic 
interference with this process leads to a drastic increase in fra-
gility of replicating chromosomes, suggesting fork reversal as 
a protective, evolutionarily conserved response to topological 
constraints in replication (Ray Chaudhuri et al., 2012). The 
identification of poly (ADP-ribose) polymerase (PARP) and 
RECQ1 as central modulators of reversed fork restart upon Top1 
poisoning further implicated fork remodeling as a genetically 
controlled, physiological response in higher eukaryotes (Berti 
et al., 2013) and revived significant interest for fork reversal 
anticancer therapies (Michaelis et al., 2001). DNA cross-linking 
agents, such as mitomycin C (MMC) and cisplatin (or cis- 
diamminedichloroplatinum [CDDP]), are also extensively used 
to treat many different cancers (Deans and West, 2011). Although 
their cytotoxicity is commonly related to the induction of inter-
strand cross-links (ICL), these drugs induce a complex combi-
nation of different adducts. ICL-inducing agents have become 
increasingly popular in basic research because of the isolation 
of numerous defects in genome stability genes sensitizing cells 
specifically to these agents and resulting in the cancer-prone 
human syndrome Fanconi anemia (FA; Deans and West, 2011). 
Finally, several additional treatments are known to damage the 
DNA bases, interfering with replication fidelity and progression 
(Hoeijmakers, 2009). Among the most investigated sources 
of base damage are UV-C irradiation, the methlyating agent 
methyl methanesulfonate (MMS), and oxidative DNA damage, 
which can be easily induced by short treatments with hydrogen 
peroxide (H2O2). Although this plethora of genotoxic agents 
share the observable ability to challenge the replication process, 
the mechanistic details of replication interference have been 
mostly studied in vitro or in model systems, and the detailed 
cellular responses have remained largely elusive in higher 
eukaryotic cells. However, mechanistic insight is required to 
inform the choice of specific chemotherapeutic regimens, to 
Figure 1. Mild genotoxic stress induces 
marked fork slowing in the absence of chro-
mosomal breakage. (A) DNA fiber spread-
ing. Statistical analysis of IdU replicated track 
length in U2OS cells, comparing not treated 
(NT) conditions with the indicated treatments. 
The labeling protocol and representative fibers 
are included in Fig. S1. At least 100 tracks 
were scored per sample. Horizontal lines 
represent the median value, and boxes and 
whiskers show 10–90th percentiles. Statistical 
analysis t test according to Mann–Whitney, 
results are ns, not significant; ****, P ≤ 0.0001. 
All experiments have been repeated at least 
twice, with very similar results. (B) PFGE analy-
sis for DNA breakage detection in untreated 
U2OS cells and upon 1-h treatment of the 
indicated doses of genotoxic treatments. 1 µM 
camptothecin (CPT) treatment is used as a posi-
tive control for DSB formation. See also Fig. S1 
for the selection of appropriate doses for each 
treatment. Fig. 4 and Fig. S4 include data on 
DDR activation possibly associated with minor 
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genotoxic treatments, we exposed the Rb/p53-proficient 
osteosarcoma cell line U-2 OS (U2OS) to a panel of clinically 
relevant genotoxic treatments (see Introduction), including 
topoisomerase inhibitors (CPT, ETP, and DOX), ICL-inducing 
agents (MMC and CDDP), DNA synthesis inhibitors (APH and 
HU), and base-damaging agents (MMS, H2O2, and UV-C irra-
diation, shortly UV). To allow the effective comparison of the 
cellular responses to these treatments, we selected for each of 
these genotoxic agents an appropriate dose that would induce 
marginal effects on cell survival and proliferation (Fig. S1 A). 
We next confirmed, by prolonged treatments and flow cytomet-
ric analysis, that the selected dose would permit completion of 
bulk genome duplication but delay transition through S phase 
(Fig. S1 B), indicating mild interference of these treatments 
with the replication process. We next used an established pro-
tocol for DNA fiber spreading analysis, after incorporation of 
halogenated nucleotides (Jackson and Pombo, 1998), to investi-
gate at single molecule level the effect of these genotoxic treat-
ments on replication fork progression (Fig. S1 C). Remarkably, 
despite the moderate effects on cell survival and cell cycle pro-
gression, all selected treatments quickly and markedly affected 
replication fork progression, spanning from 25% (H2O2) to 80% 
(HU) reduction in fork speed (Fig. 1 A). 1-h treatment with the 
selected dose of each genotoxic agent did not reveal any signifi-
cant increase in the level of chromosomal breakage above back-
ground levels, as assessed by pulsed field gel electrophoresis 
(PFGE; Fig. 1 B). Minor DSB levels, close to the detection level 
of this approach (100 DSB/cell; Ray Chaudhuri et al., 2012), 
possibly induced by a subset of drugs are addressed by further 
experiments described below (see Structural determinants of 
ATR and ATM activation upon genotoxic treatments in human 
cells). Collectively, these data suggest that mild treatments with 
cancer chemotherapeutics and other genotoxic agents induce a 
marked slowdown of replication fork progression, largely un-
coupled from fork breakage.
Fork slowing by all genotoxic treatments 
is associated with fork uncoupling and 
accumulation of postreplicative ssDNA gaps
We next used psoralen cross-linking coupled to EM (Neelsen 
et al., 2014) to investigate in vivo possible alterations of replica-
tion fork architecture associated with the observed fork slowing. 
This technique allows reliable identification of ssDNA regions 
on DNA molecules, based on local reduction of filament thick-
ness (Neelsen et al., 2014 and references therein). Short (Y40 nt) 
ssDNA regions are expected to arise during lagging strand 
synthesis in eukaryotes and are promptly detected at a subset of 
unperturbed replication forks (untreated). However, all geno-
toxic treatments induced a significant accumulation of larger 
ssDNA stretches at replication forks, increasing their median 
length by 1.5–2-fold and leading to occasional ssDNA stretches 
up to 500-nt long (Fig. 2, A and B). Thus, whether replication 
stress is induced by DNA damage, topological stress, or enzy-
matic inhibition of DNA synthesis, replication fork uncoupling 
is a common structural feature associated with genotoxic treat-
ments in human cells. It is likely that the length of these ssDNA 
regions reflects how strongly each treatment interferes with 
in genome stability and cancer (León-Ortiz et al., 2014; Zeman 
and Cimprich, 2014; Neelsen and Lopes, 2015). However, key 
biological questions remain open, such as whether reversed forks 
are detected upon other types of replication stress and, in that 
case, whether their stability and restart are controlled by a com-
mon set of cellular factors. Furthermore, although several factors 
were shown to induce replication fork reversal in biochemical 
reconstitution—including RECQ helicases, SWI/SNF (Switch/
Sucrose Nonfermentable) proteins, and FANCM (Kanagaraj 
et al., 2006; Machwe et al., 2006; Ralf et al., 2006; Gari et al., 
2008; Blastyák et al., 2010; Bugreev et al., 2011; Bétous et al., 
2012, 2013; Ciccia et al., 2012; Burkovics et al., 2014)—the lack 
of a reliable readout for fork reversal in vivo has so far hampered 
the identification of fork reversing activities in the living cell.
Several homologous recombination (HR) mechanisms 
have been proposed to assist replication restart upon fork stall-
ing or collapse (Petermann and Helleday, 2010). The function of 
HR factors in replication has been consistently related to DSB 
formation at stalled forks, in light of the known involvement of 
HR in DSB repair. However, growing evidence suggests a DSB 
repair-independent role for HR factors in replication stress. The 
central vertebrate recombinase RAD51 is detected on chromatin 
during unperturbed replication and is recruited to stalled forks 
upstream of DSB formation (Hashimoto et al., 2010; Petermann 
et al., 2010). Upon prolonged fork stalling, HR factors—as well 
as numerous FA factors—are required to prevent excessive 
nucleolytic degradation of nascent strands and this function can 
be genetically uncoupled from DSB repair (Hashimoto et al., 
2010; Schlacher et al., 2011, 2012). Furthermore, HR factors 
reportedly involved in DSB resection (i.e., MRE11, NBS1, and 
CtIP) were recently involved in fork processing and ATR sig-
naling (Shiotani et al., 2013; Murina et al., 2014; Yeo et al., 
2014). Most recently, the HR cancer susceptibility gene BRCA1 
was shown to promote specific recombination events at Tus/
Ter-stalled mammalian forks, which can be distinguished from 
canonical DSB repair (Willis et al., 2014). Altogether, these 
recent observations suggest the mechanistic involvement of HR 
and possibly other FA factors in replication fork metabolism, 
independently from repair of chromosomal breakage.
In this work, we show that replication fork reversal is a 
global response to several different sources of replication stress. 
We suggest single-stranded DNA (ssDNA) accumulation as com-
mon precursor of fork reversal upon different types of genotoxic 
stress. We identify the central recombinase RAD51 as stable 
replisome component, independent of fork breakage, and as first 
cellular factor assisting in vivo the reversal process. Furthermore, 
we extend the role of PARP and RECQ1 to the controlled restart 
of reversed forks induced by different treatments.
Results
Sublethal doses of genotoxic treatments 
in human cells consistently induce 
replication fork slowing, without detectable 
chromosomal breakage
To investigate at the molecular level replication interference 
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Furthermore, careful observation of the replicated duplexes in 
the analyzed population of intermediates revealed that 20–30% 
of the replication forks exposed at least one postreplicative 
continuous DNA synthesis on the leading strand (Lopes et al., 
2006), via modulating template availability, polymerase pro-
cessivity, nucleotide abundance, and/or torsional constraints. 
Figure 2. Genotoxic treatments lead to extended 
ssDNA regions at replication forks and ssDNA gaps on 
replicated duplexes. (A and C) Electron micrographs of 
representative replication fork from U2OS cells, after 1-h 
treatment with 100 nM APH (A) and 50 µM MMS (C), 
respectively. P indicates the parental duplex, whereas D 
indicates daughter duplexes. The black arrow points to 
an ssDNA region at the fork, whereas the white arrow 
indicates an ssDNA gap on a replicated duplex. The 
relevant portions of the molecules are magnified in 
the insets. Bars: (main images) 0.5 kb; (insets) 0.2 kb. 
(B) Graphical distribution of ssDNA length at the junc-
tion (black arrow in A) in not treated (NT) U2OS cells 
and upon the indicated treatments (UV pulse or 1-h treat-
ment). Only molecules with detectable ssDNA stretches 
are included in the analysis. The lines show the median 
lengths of the ssDNA regions at the fork in the specific 
set of analyzed molecules. Statistical analysis t test 
according to Mann–Whitney results are *, P ≤ 0.1; 
**, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001. 
In brackets, the total number of analyzed molecules is 
given. (D) Frequency of replication forks with at least 
one ssDNA gap (white arrow in C) in untreated U2OS 
cells and upon the indicated treatments. In brackets, the 
total number of analyzed molecules is given. Similar re-
sults to those displayed in B and D were obtained in at 
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reannealing of parental strands and simultaneous annealing 
of the newly synthesized strands (Ray Chaudhuri et al., 2012; 
Neelsen and Lopes, 2015). Although reversed forks were also 
reported upon genetic perturbations associated with early 
tumorigenesis (Neelsen et al., 2013a,b), a key open question was 
whether this DNA transaction was induced by any treatment 
interfering with the replication process (León-Ortiz et al., 2014). 
We now report high frequency of replication fork reversal (15–
30%) upon all tested genotoxic treatments (Fig. 3 B). Consider-
ing the calculated number of active replication forks in a typical 
S phase (3,000–12,000; Ge and Blow, 2010), this corresponds 
to Y500–4,000 reversed forks per cell, under different types 
of mild genotoxic stress compatible with cell proliferation and 
survival (Fig. S1 A). As previously reported for Top1 poisoning 
(Ray Chaudhuri et al., 2012), the observed frequency of fork 
reversal is already high at sublethal doses of genotoxic agents 
and does not significantly increase with a 10-fold higher dose 
(Fig. S3 A). In vivo cross-linking of RI before extraction ex-
cludes that these structures form in vitro during sample prepara-
tion (Neelsen et al., 2014). Furthermore, the relative abundance 
of reversed forks is not changed by omitting from the EM pro-
cedure the RI-enrichment step (Fig. S3 B; Neelsen et al., 2014). 
ssDNA gap, corresponding to a two- to threefold increase over 
the level observed in untreated cells (Fig. 2, C and D; and 
Fig. S2 A). Interestingly, the frequency of postreplicative ssDNA 
gaps upon different treatments generally correlated with the 
length of the ssDNA regions observed at the fork (Fig. 2, B and 
D), suggesting DNA synthesis repriming events at uncoupled 
replication forks, in line with previous observations in yeast 
(Lopes et al., 2006). However, the size of these ssDNA gaps 
varied significantly between different drugs (Fig. S2 B), possi-
bly reflecting DNA synthesis restart at a different distance from 
the original block and/or damage-specific repair and process-
ing events. Very similar observations on ssDNA accumulation 
at replication intermediates (RIs) were made on the untrans-
formed human epithelial cell line RPE-1 treated with a subset 
of the genotoxic agents (Fig. S2, C and D).
Replication fork reversal is a widespread 
global response to replication stress in 
human cells
We recently reported that—upon mild, clinically relevant doses 
of Top1 poisons—a large fraction of forks undergo rever-
sal (Fig. 3 A), i.e., they form a fourth regressed arm, by local 
Figure 3. All tested sources of genotoxic 
stress lead to frequent replication fork reversal. 
(A) Electron micrograph of a representative 
reversed replication fork from U2OS cells treated 
for 1 h with 20 nM ETP. P indicates the paren-
tal duplex, D indicates daughter duplexes, and 
R indicates the regressed arm. Bar, 0.5 kb. 
(B and C) Frequency of reversed replication 
forks in U2OS (B) or RPE-1 cells (C) either not 
treated (NT) or upon the indicated treatments 
(UV pulse or 1-h treatment). In brackets, the 
total number of analyzed molecules is given. 
Above each column, the percentage of re-
versed forks is indicated. Similar results were 
obtained in at least one independent experi-
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Figure 4. Differential ATR and ATM activation upon different genotoxic treatments, despite similar structural features of RIs. (A) Immunoblot for ATR 
(pCHK1) and ATM (pKAP1) activation and total DDR proteins (CHK1 and KAP1) in not treated (NT) U2OS cells and upon the indicated treatments 
(UV pulse or 1-h treatment). RPA32 (RPA) phosphorylation at S4/S8 indicates ATM/DNA-dependent protein kinase (DNA-PK) activation and is typically used 
as a DSB marker. Total RPA32 levels (and phosphorylation-associated mobility shift) are also displayed. 1 µM CPT treatment is used as positive control 
for full DDR activation. TFIIH is used as a loading control. (B) Native immunofluorescence staining for cells grown with 10 µM BrdU for 48 h and treated 
with the indicated drugs for 1 h. Red staining, G-H2AX; green staining, BrdU (ssDNA); blue, DAPI. Bar, 15 µM. (C) Relative quantification of double-negative 
cells and cells positive for G-H2AX, native BrdU staining (natBrdU), or both for the experiment in B. The data shown are from a single representative 
experiment out of three repeats, with n > 100. (D) Flow cytometry analysis of DNA synthesis (EdU), DNA content (DAPI), and DDR activation (G-H2AX) in 
untreated U2OS cells and upon the indicated treatments. Dashed line indicates threshold for EdU incorporation and G-H2AX positivity, respectively. See 
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Importantly, very similar frequencies of reversed forks were 
induced by genotoxic treatments in RPE-1 cells (Fig. 3 C), ex-
tending our observations to noncancerous cells. Thus, replica-
tion fork reversal genuinely represents a general, widespread, 
physiological response to replication interference in human 
cells. With the exception of CPT and H2O2, which induced sig-
nificantly longer regressed arms, the length of the fourth arm 
at reversed forks averaged around 300 bp in all conditions and 
only rarely exceeded 1 kb (Fig. S3 C). We also investigated the 
possible presence of ssDNA on the regressed arm, which may 
result from reversal of uncoupled forks and/or nucleolytic pro-
cessing of the regressed arm. We observed that 20–50% of the 
regressed arms exposed ssDNA ends or gaps, whereas <15% 
were entirely single stranded (Fig. S3, D and E). The relative 
proportion of these categories shows subtle variations, but no 
strong bias, among the different treatments.
Structural determinants of ATR and ATM 
activation upon genotoxic treatments in 
human cells
Activation of the ATR-mediated replication checkpoint has 
been linked to excess ssDNA at RIs (Zou and Elledge, 2003). 
However, ATR activation requires multiple protein–protein 
interactions and recently revealed unexpected complexity (Nam 
and Cortez, 2011; Shiotani et al., 2013; Kumar et al., 2014). Fur-
thermore, ATR activation can also be a secondary consequence 
of nucleolytic processing of DSB, frequently associated with 
prolonged replication stress, limiting our mechanistic under-
standing of ATR activation upon replication interference. We 
thus reckoned that our extensive in vivo RI visualization under 
mild genotoxic treatments, i.e., not associated with detectable 
chromosomal breakage, could provide valuable information on 
the structural determinants of ATR activation. We noted that, 
despite consistent fork slowing, frequent fork reversal, and ac-
cumulation of ssDNA upon all genotoxic treatments, several 
treatments (ETP, DOX, MMC, CDDP, and APH) induced no—
or marginal—ATR activation, as detected by phosphorylation 
of its direct target CHK1 (Fig. 4 and Table 1). Furthermore, 
the marked CHK1 phosphorylation detected upon HU and UV 
treatment was not specifically associated with excessive ac-
cumulation of ssDNA regions at uncoupled forks, at postrep-
licative gaps, or at regressed arms (Fig. 4 A; Fig. 2, B and D; 
Fig. S2, A and B; Fig. S3 E; and Table 1). Differently from 
ssDNA visualization by EM (Figs. 2 and S2), detection of total 
exposed ssDNA by native BrdU staining revealed marked dif-
ferences among the treatments. Although BrdU staining and 
G-H2AX staining correlated at the population level, they colo-
calized only in a minority of the cells (Fig. 4, B and C), further 
uncoupling ssDNA accumulation from ATR signaling. Sur-
prisingly, we also found no strict correlation across treatments 
between impairment of DNA synthesis (5-ethynyl-2-deoxy-
uridine [EdU] incorporation) and ATR activation (G-H2AX), 
as APH treatment severely impairs DNA synthesis in the ab-
sence of detectable ATR activation (Fig. 4, B–D). Marked ATR 
activation upon HU and UV treatments is also not an indirect 
consequence of chromosomal breakage, as it was associated 
with no detectable accumulation of DSB by PFGE (Fig. 1 B) or 
phosphorylation of RPA32 on S4/S8 (Fig. 4; see also Fig. 6 B), 
a recognized DSB marker (Oakley and Patrick, 2010). Overall, 
ATR activation in our experimental conditions does not directly 
mirror the extent of replication interference, nor the amount of 
ssDNA detected at RIs (Table 1), and likely reflects yet-undefined 
signaling determinants that escape systematic cell-based and 
single-molecule analyses.
We also detected phosphorylation of ATM and its target 
KAP1 upon mild treatments with CPT and UV, albeit not 
accompanied by RPA S4/S8 phosphorylation or detectable DSBs 
(Figs. 1 B and 4). To assess the possibility that both approaches 
may not be sensitive enough to reveal minor DSB levels, we in-
creased 10-fold the dose of each genotoxic treatments and reas-
sessed physical chromosomal breakage and cellular responses. 
In the case of CPT, DOX, H2O2, and UV, the higher doses did 
lead to detectable DSBs, expectedly associated with ATM, 
KAP1, and RPA32-S4/S8 phosphorylation (Fig. S4). Lack of 
S4/S8 phosphorylation upon DOX treatments may reflect spe-
cific effects of this drug in DSB signaling. Interestingly, at 
higher doses, MMS also induced ATM/KAP1 phosphorylation 
without detectable DSB and RPA32 S4/S8 phosphorylation 
(Fig. S4), as already seen for mild CPT and UV treatments 
(Figs. 4 A and S4), supporting the notion that under certain con-
ditions, replication stress can activate ATM in the absence of 
DSB (Table 2; Ray Chaudhuri et al., 2012). However—as for 
the strong ATR activation upon UV and HU treatments—we 
could not unambiguously associate this DSB-independent ATM 
Table 1. Relevant parameters for ATR activation upon a subset of genotoxic treatments
Parameter Approach Figure NT MMC (200 nM) APH (100 nM) CPT (25 nM) HU (0.5 mM)
Fork reversal EM analysis 3, B and C /+ ++ ++ ++ ++
Fork slowing DNA fiber spreading 1 A  ++ ++ + +++
Impaired DNA synthesis EdU incorporation 
(FACS)
4 D  /+ ++ + +++
ssDNA at forks EM analysis 2, A and B; S2; 
and S3
 + + + +
Total exposed ssDNA Native BrdU staining 4 B    ++ ++
ATR signaling at forks iPOND G-H2AX 6 B  /+ ND ++ +++
ATR signaling total WB pCHK1 4 A    + +++
ATR signaling total IF/FACS G-H2AX 4, B–D    ++ ++
Parameters were assessed by different investigation methods, as displayed in the indicated figures. /+, +, ++, and +++ indicate increasingly clear phenotypes. 
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promote fork restart and progression, irrespective of whether 
fork reversal is induced by topological stress (CPT; Berti et al., 
2013), DNA cross-linking (MMC), or DNA synthesis inhibi-
tion (HU).
The human recombinase RAD51 is 
recruited to replication forks in the 
absence of DSBs and modulates fork 
progression and integrity
The extensive EM analysis described in this work identifies fork 
uncoupling and reversal as common parallel transactions upon 
replication interference by various genotoxic treatments. We 
tested the functional correlation of these events by plotting the 
frequency of reversed forks versus the median size of ssDNA 
stretches at the forks for all EM samples analyzed (Fig. 6 A). 
This analysis shows that our EM measurements of fork reversal 
and ssDNA accumulation were highly reproducible in indepen-
dent experiments for each drug. Although a general association 
of the two events is not unexpected, the striking correlation that 
we found between the two parameters (Fig. 6 A) prompted us to 
investigate whether they were not only correlatively associated, 
but rather mechanistically linked. Accumulation of ssDNA is 
a crucial structural feature of upstream intermediates in DSB 
repair by HR and is actively induced by DNA end resection 
for the controlled loading of the central recombinase factor 
RAD51, which then drives homology-directed strand inva-
sion (Symington and Gautier, 2011). We thus tested whether, 
in our experimental conditions, RAD51 could be detected at 
replication forks, as suggested by a recent screening (Alabert 
et al., 2014). Using an iPOND approach with different labeling 
protocols (Sirbu et al., 2011; Fig. S5 C), we detected mild, but 
reproducible, RAD51 association with replication forks even in 
unperturbed conditions, which was lost—as for other replisome 
components, e.g., proliferating cell nuclear antigen—upon 
thymidine chase, and enriched by mild treatments with HU, 
MMC, and CPT (Fig. 6 B). Upon mild HU and CPT treatments, 
G-H2AX is clearly detected at forks, confirming our results on 
ATR activation (Fig. 4). However, differently from acute treat-
ments affecting fork integrity (1 µM CPT), no RPA32-S4/8 
phosphorylation is present on EdU-labeled DNA upon any of 
the mild genotoxic treatments, confirming that the enrichment 
of RAD51 at forks facing replication stress is uncoupled from 
fork breakage (Fig. 6 B). Similarly, we observed by single-
cell labeling that RAD51 is chromatin loaded in unperturbed 
S phase cells (EdU+) and is enriched in numerous foci upon 
signaling to any specific structural feature detectable by EM 
analysis (Table 2). Finally, APH and ETP, despite their marked 
effect on DNA synthesis, fork uncoupling, and reversal already 
at low doses (Figs. 1 A, 2 B, 3 B, and 4 C), did not induce de-
tectable ATR or ATM activation even at 10-fold higher doses. 
Altogether, these data suggest that fork slowing, fork reversal, 
and ssDNA accumulation are by themselves nonpredictive 
parameters for ATR or ATM activation upon replication stress.
RECQ1 and PARP activities regulate 
the restart of reversed forks induced by 
different types of replication stress
After identification of replication fork reversal as a frequent 
DNA transaction upon Top1 poisoning in human cells (Ray 
Chaudhuri et al., 2012), we reported reversed fork accumula-
tion in these conditions to depend on transient PARP-mediated 
inhibition of the specific restart activity of the RECQ1 heli-
case, thus linking fork restart to DNA repair and PARP inacti-
vation (Berti et al., 2013). We therefore decided to investigate 
by DNA fiber and EM analysis whether similar mechanisms 
would control the restart of reversed forks observed upon other 
genotoxic treatments. We focused this analysis on MMC and 
HU, as prototypes of replication stress induced by template 
cross-linking and DNA synthesis inhibition, respectively, thus 
mechanistically distinct from the replication stress induced by 
Top1 poisons. As previously reported for CPT (Sugimura 
et al., 2008; Ray Chaudhuri et al., 2012), PARP inactivation by 
olaparib largely abolished MMC-induced fork slowing and 
only partially restored replication fork progression in HU, in 
which nucleotide shortage cannot be overcome (HU; Fig. 5 A). 
Importantly, the effect of olaparib upon both treatments was 
dependent on the RECQ1 helicase, showing that fork slowing 
upon different sources of replication stress is an active process 
mediated by transient PARP-mediated inhibition of RECQ1 
activity (Fig. 5 A). Furthermore, PARP inactivation markedly 
reduced reversed fork accumulation upon MMC and HU treat-
ments. RECQ1 depletion induced by itself a threefold accumu-
lation of reversed forks under unperturbed conditions (Fig. 5 B), 
associated with mild ATM/KAP1 phosphorylation and no ac-
cumulation of ssDNA gaps (Fig. S5, A and B). Importantly, 
RECQ1 depletion largely abolished PARP requirement for re-
versed fork accumulation upon both treatments and prevented 
the rapid decline in reversed fork frequency observed upon 
drug removal (Fig. 5 B). Altogether, these data strongly suggest 
that PARP-controlled RECQ1 activity is largely responsible to 
Table 2. Relevant parameters for ATM activation upon a subset of genotoxic treatments
Parameter Approach Figure NT MMC (200 nM) DOX (50 nM) UV (5 J/m2) CPT (25 nM) CPT (1 µM)
Fork reversal EM analysis 3, B and C /+ ++ ++ ++ ++ ++
DSBs PFGE 1 B and S4   /+   ++
ATM signaling at forks iPOND pRPA32 6 B      ++
ATM signaling total WB pRPA32 4 and S4      ++
ATM signaling total WB pKAP1 4 and S4   +/ + +/ ++
ATM signaling total WB pATM S4   +/ + + ++
Parameters were assessed by different investigation methods, as displayed in the indicated figures. /+, +, ++, and +++ indicate increasingly clear phenotypes. NT, 
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and replication potential (Fig. S5, D and E). Furthermore, stable 
expression of exogenous, siRNA-resistant RAD51 completely 
restored the frequency of CPT-induced fork reversal observed 
in control cells (Fig. 7 C). RAD51 depletion also abolished 
the increased level of reversed forks observed in unperturbed 
RECQ1-depleted cells (Fig. S5 F), proving that RAD51 is 
required for replication fork reversal upon both endogenous and 
exogenous genotoxic stress. Importantly, upon all tested treat-
ments, defective fork reversal was accompanied by a signifi-
cant increase in RIs displaying long ssDNA regions at the fork 
(Fig. 7, D and E), strongly suggesting that uncoupled forks 
are precursors of RAD51-mediated fork reversal. Despite the 
effects on replication fork remodeling, RAD51 depletion had 
no noticeable impact on the abundance of the postreplicative 
ssDNA gaps induced by the genotoxic drugs (Fig. 7 F), differ-
ently from what previously shown in yeast and Xenopus egg 
extracts (Hashimoto et al., 2010). Altogether, these data imply 
RAD51-mediated recombinational mechanisms in the remodel-
ing of uncoupled replication forks upon different types of rep-
lication stress.
Discussion
In this study, we have performed an unprecedented structural 
survey on the impact of genotoxic treatments on the replication 
process in human cells. The differential sensitivity of cancer 
and normal cells, often related to cancer-specific defects in the 
DNA damage response (DDR), is uncovered at relatively mild 
both mild and acute genotoxic treatments (Fig. 6 C). siRNA-
mediated down-regulation of RAD51 largely abolished active 
replication fork slowing observed upon MMC and CPT treat-
ments, whereas had no significant effect when fork progression 
was physically impaired by nucleotide shortage (HU), suggest-
ing RAD51 loading as a crucial modulator of fork progression 
upon genotoxic stress (Fig. 6 D). Furthermore, RAD51 deple-
tion also impacted on replication fork integrity, leading to a sig-
nificant induction of DSBs already in unperturbed conditions, 
with marginal further increase observable upon exogenous geno-
toxic stress (Fig. 6 E).
RAD51 is required to limit replication fork 
uncoupling and drive fork reversal upon 
different genotoxic treatments
In light of our previously reported data upon Top1 poisoning 
(Ray Chaudhuri et al., 2012), the observations reported here 
were highly suggestive of a role for RAD51 in replication fork 
reversal. We thus tested the hypothesis that, by analogy to HR 
mechanisms at DSBs, RAD51 could be loaded on extended 
ssDNA regions at uncoupled forks and drive fork reversal by 
template reannealing. EM analysis of U2OS cells treated with 
CPT, MMC, or HU upon siRNA-mediated RAD51 deple-
tion revealed that effective fork reversal upon all treatments 
strictly requires RAD51 (Fig. 7 A). This held true using dif-
ferent siRAD51 oligonucleotides and extracting RI 24 h after 
siRNA transfection (Fig. 7 B), when protein depletion was yet 
incomplete and cells showed no alteration in their cell cycle 
Figure 5. RECQ1 and PARP activity control 
replication fork progression and accumula-
tion/restart of reversed forks upon differ-
ent types of genotoxic stress. (A) Statistical 
analysis of IdU track length measurements, 
according to the labeling protocol in Fig. S1, 
in U2OS cells stably transduced (shRNA) for 
Luciferase (shLuc) or RECQ1 (shRECQ1) deple-
tion. 200 nM MMC and 500 µM HU were op-
tionally added concomitantly with the second 
label (IdU). The PARP inhibitor olaparib (Ola; 
10 µM) was optionally added 2 h before CldU 
labeling and maintained during labeling. At 
least 100 tracks were scored for each dataset. 
Horizontal lines represent the median value, 
and boxes and whiskers indicate the 10–90th 
percentiles. t test according to Mann–Whitney; 
ns, not significant; ****, P < 0.0001. Similar 
results were obtained in at least one indepen-
dent experiment. (B) Frequency of reversed 
forks detected by EM in U2OS cells stably 
transfected (shRNA) for Luciferase or RECQ1 
depletion. The cells were optionally treated for 
1 h with 200 nM MMC or 500 µM HU, after 
an optional 2-h pretreatment with olaparib. Re-
versed fork restart was assessed by measuring 
the frequency of reversed forks 3 h after drug 
removal (release [Rel.]). In brackets, the total 
number of analyzed molecules is given. Above 
each column, the percentage of reversed forks 
is indicated. Similar results were obtained in 
at least one independent experiment. RECQ1 
levels after shRNA-mediated depletion were 
detected by immunoblotting. TFIIH was used 
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Figure 6. RAD51 is present at forks upon mild genotoxic stress and modulates fork progression and integrity. (A) Linear regression analysis shows strict 
direct correlation (P < 0.0001) between accumulation of ssDNA at the fork (median values of ssDNA regions at the junction) and frequency of fork reversal. 
Results from two independent experiments are displayed for untreated U2OS cells and for each genotoxic treatment. (B) HEK293T cells were EdU-labeled 
as indicated in Fig. S5 C and treated with sublethal doses of genotoxic drugs (0.5 mM HU, 200 nM MMC, or 25 nM CPT). Proteins and relative post-
translational modifications associated with replication forks were isolated by iPOND procedure and detected with the indicated antibodies. The thymidine 
(Thy; 10 µM) chase experiment is used to discriminate proteins associated with chromatin behind replicating forks. In the control (Ctrl) experiment, the 
click reaction is performed using DMSO instead of biotin azide. 1 µM CPT treatment is used as positive control to induce high replication stress and DSBs. 
(C) Immunofluorescence staining for U2OS cells grown on coverslips and treated with the indicated drugs for 1 h. Red staining, RAD51; green staining, 
EdU; blue, DAPI. Bar, 15 µM. (D) DNA fiber spreading. Statistical analysis of IdU replicated track length in U2OS cells, comparing not treated (NT) 
conditions with the indicated treatments. U2OS cells were transfected with siRNA against luciferase (siLuc) or RAD51 (siRAD51) 24 h before CldU or IdU 
labeling. At least 100 tracks were scored per sample. Horizontal lines represent the median value, and boxes and whiskers indicate 10–90th percentiles. 
Statistical analysis: one-way ANOVA; ns, not significant; ***, P ≤ 0.001. (E) PFGE analysis for DNA breakage detection in untreated U2OS cells and upon 
1-h treatment with indicated doses of genotoxic treatments. U2OS cells were transfected with siRNA against luciferase or RAD51 24 h before treatments. 
1 µM camptothecin (CPT) treatment is used as a positive control for DSB formation. The graph shows quantitative DSB induction from three independent 
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doses of the genotoxic agents used in cancer therapy (Bouwman 
and Jonkers, 2012 and references therein). We thus decided to 
investigate the effects of different genotoxic agents at doses that 
caused minimal lethality to the Rb/p53-proficient osteosarcoma 
human cell line, mostly used in this study (U2OS). These con-
ditions enabled us to dissect the consequences of replication 
interference in the absence of detectably compromised chro-
mosome integrity.
Despite diverse modes of interference with DNA synthe-
sis (base damage, DNA intercalation and cross-linking, nucleo-
tide depletion, polymerase inhibition, and torsional constraints), 
all tested genotoxic agents lead to strikingly similar mechanis-
tic consequences on the replication process, i.e., marked fork 
slowing, ssDNA accumulation, and fork reversal. Importantly, 
these conclusions hold true in a nontransformed human cell 
line (RPE-1). The rapid accumulation of replication forks with 
extended ssDNA at the junction may represent the indirect 
consequence of continued helicase activity ahead of the fork, 
whereas DNA synthesis is asymmetrically delayed by the geno-
toxic treatment (Fig. 8), as reported in UV-irradiated yeast cells 
(Lopes et al., 2006). However, the extent of fork uncoupling 
may also be regulated by replisome-associated factors, specifi-
cally engaged in the replication process upon genotoxic stress, 
as recently suggested for the minichromosome maintenance–
associated FA factor FANCD2 (Lossaint et al., 2013). Further-
more, the extent of ssDNA at replication forks challenged by 
genotoxic stress could be controlled by regulated nucleolytic 
processing of newly synthesized DNA, which becomes particu-
larly evident after prolonged stress and pathological conditions 
(Schlacher et al., 2011, 2012). Interestingly, several factors 
previously involved in DSB resection—e.g., MRE11, NBS1, 
and CtIP—have been recently involved in fork metabolism and 
ATR activation upon genotoxic stress (Schlacher et al., 2011; 
Shiotani et al., 2013; Murina et al., 2014; Yeo et al., 2014), sug-
gesting that ssDNA regions at damaged replication forks may 
be subjected to similar processing as DSB.
Indeed, one important implication of our data is that repli-
cation fork remodeling upon genotoxic stress shares an impor-
tant mechanistic step with DSB repair, i.e., RAD51-mediated 
strand invasion, rapidly and effectively leading to replication 
fork reversal (Fig. 8; Neelsen and Lopes, 2015). As originally 
suggested by (Higgins et al., 1976), remodeling of uncoupled 
replication forks in human cells, besides limiting excessive 
ssDNA accumulation, would also allow more time for template 
repair and promote efficient DNA damage bypass directly at 
the fork, thus limiting reliance on postreplicative repair. In-
triguingly, replication forks in wild-type yeast cells—which 
are devoid of PARPs—do not detectably undergo reversal 
upon most genotoxic treatments. In keeping with our model, 
yeast cells accumulate much longer ssDNA stretches at the 
junction and postreplicative ssDNA gaps, favoring fork restart 
by repriming (Sogo et al., 2002; Lopes et al., 2006). In line 
with this notion, genetic inactivation of HR-mediated repair 
(RAD51) upon genotoxic stress results in marked accumula-
tion of postreplicative gaps in Saccharomyces cerevisiae 
(Lopes et al., 2006; Hashimoto et al., 2010) but not in human 
cells (Fig. 7 F).
Both aberrant RIs consistently and abundantly detected 
upon all tested genotoxic treatments—i.e., forks with extended 
ssDNA regions and reversed forks—carry intrinsic signaling 
potential. Excess ssDNA at replication forks has been linked 
to ATR activation (Zou and Elledge, 2003), whereas the for-
mation of a new DNA end at regressed arms may potentially 
activate ATM in the absence of DSBs. Albeit conceptually 
attractive, our structural data argue against both of these models. 
Although ssDNA accumulation—at forks, gaps, or regressed 
arms—was observed at similar extents with several genotoxic 
treatments, some of them induced strong ATR activation (UV 
and HU), whereas others (APH and ETP) failed to detectably 
activate ATR, even at doses 10-fold higher than those required 
to drastically impair fork progression. Compared with EM ana-
lysis of ssDNA at RI, total ssDNA detection by native BrdU 
staining shows more pronounced differences among treatments 
and a stronger correlation with ATR activation, suggesting that 
ssDNA accumulation uncoupled from RI may be more relevant 
for ATR signaling. However, cells scoring positive in this assay 
still represent a minority of those showing G-H2AX. Thus, 
ATR signaling in these conditions seems largely uncoupled 
from ssDNA/RPA accumulation, in keeping with other studies 
challenging this dogma (Ball et al., 2005; Recolin et al., 2012), 
and may reflect alternative yet-undefined mechanisms (Kumar 
et al., 2014). Similarly, high frequencies of reversed forks are 
observed with all treatments but are associated with detectable 
ATM activation only upon exposure to CPT and UV. Thus, 
besides these basic structural determinants (ssDNA and DNA 
ends, respectively), ATR and ATM activation at replication 
forks may require additional molecular features, which may be 
difficult to identify by EM analysis. Alternatively, checkpoint 
activation may entail a specific chromatin or topological con-
text, or recruitment/removal of cellular factors at/from replica-
tion forks, which may only occur under specific conditions.
We show that the same molecular mechanism—i.e., 
PARP-regulated RECQ1 helicase activity—is largely responsi-
ble for the accumulation of reversed forks upon different types 
of genotoxic stress and to restart these forks once the stress is 
relieved (Figs. 5 and 8; Berti et al., 2013). An important mecha-
nistic implication of these findings is that local PARP activation 
must result from a common structural determinant induced by 
all treatments, including genotoxic agents that do not directly 
cause DNA damage or breakage (e.g., HU). The unambiguous 
identification of this structural determinant will require further 
investigation. It should be noted, however, that the discontinui-
ties present on nascent strands—as well as the DNA end at the 
regressed arm upon reversal—may be structurally identical to 
the strand breaks that are reportedly responsible for PARP ac-
tivation in DNA repair (Pines et al., 2013) and that four-way 
junctions carry by themselves the potential to activate PARP 
(Lonskaya et al., 2005).
Our data clearly consolidate previous evidence that RAD51 
is a stable component of replicating chromatin in metazoan, 
independently of fork breakage (Hashimoto et al., 2010; 
Petermann et al., 2010; Alabert et al., 2014). How is RAD51 re-
cruited to uncoupled forks to promote template reannealing and 
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Figure 7. RAD51 is required to convert uncoupled forks into reversed forks in response to different genotoxic treatments. (A–C) Frequency of reversed rep-
lication forks detected by EM in U2OS cells. In A, U2OS cells were transfected with Luciferase siRNA (siLuc) or RAD51siRNA (siRAD51) 72 h before DNA 
extraction from untreated cells or cells treated with 25 nM CPT, 200 nM MMC, or 500 nM HU for 1 h. In B, U2OS cells were transfected with Luciferase 
or RAD51 siRNA 24 h before treatment with 25 nM CPT for 1 h. In C, U2OS cells containing an empty vector, and U2OS cells expressing exogenous 
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for the same DSB repair-independent fork protection mechanism 
(Schlacher et al., 2012). Intriguingly, inactivation of the RAD51 
paralogue XRCC3 in DT40 cells phenocopies PARP inactivation 
in suppressing fork slowing by Top1 poisons (Sugimura et al., 
2008). Based on all this evidence, it will be a crucial challenge 
for future studies to assess in vivo the contribution of individual 
HR/FA factors in replication fork remodeling upon different 
types of genotoxic stress, by possibly mediating RAD51 loading or 
stabilization at fork-associated ssDNA regions (Fig. 8). In this 
view, these factors could contribute to genome stability by sup-
porting DNA damage tolerance and preventing DSB formation, 
besides their reported role in repairing chromosomal breaks.
the total number of analyzed molecules is given. Above each column, the percentage of reversed forks is indicated. Similar results were obtained in at 
least one independent experiment. RAD51 levels after siRNA-mediated depletion were detected by immunoblotting. B-Tubulin is used as a loading control. 
EV, empty vector. (D) Electron micrograph of a representative replication fork with an extended ssDNA region at the junction (black arrow, magnified in 
the inset) upon RAD51 depletion and treatment with 25 nM CPT for 1 h. Bars: (main image) 0.5 kb; (inset) 0.2 kb. P indicates the parental duplex, and 
D indicates daughter duplexes. (E) Graphical distribution of ssDNA length at the junction (black arrow in C) in U2OS cells transfected with Luciferase siRNA 
and RAD51 siRNA and treated with 25 nM CPT, 200 nM MMC, and 500 nM HU for 1 h. The lines show the median length of the ssDNA region at the fork 
in the specific set of analyzed molecules. Statistical analysis t test according to Mann–Whitney, results are **, P ≤ 0.01; ***, P ≤ 0.001. Similar results 
were obtained in at least one independent experiment. (F) Frequency of replication forks with ssDNA gaps (Fig. 2 C and Fig. S2) in U2OS cells transfected 
with Luciferase or RAD51 siRNA 48 h before treatment with 25 nM CPT, 200 nM MMC, or 500 nM HU for 1 h. Similar results were obtained in at least 
one independent experiment. NT, not treated.
 
regions—an ideal target for RAD51 binding—may by itself 
explain RAD51 loading to forks upon various genotoxic treat-
ments. However, the competition with RPA for ssDNA bind-
ing in classical HR-dependent DSB repair implies that RAD51 
loading is assisted by accessory proteins, such as the RAD51 
paralogues and/or the cancer susceptibility genes BRCA1 and 
BRCA2 (Suwaki et al., 2011). Importantly, many of these factors 
have been recently reported to play a pivotal role also at stalled 
replication forks, promoting recombinational mechanisms that 
are structurally and/or genetically distinct from canonical DSB 
repair (Schlacher et al., 2011; Adelman et al., 2013; Willis et al., 
2014). Furthermore, several additional FA factors are required 
Figure 8. Schematic model for replication fork re-
versal and restart upon different types of replication 
stress. Template damage, DNA synthesis inhibition, 
or torsional stress rapidly impair symmetric elongation 
of nascent strands and induce replication fork uncou-
pling, leading to extended ssDNA regions at the fork. 
Controlled nascent strand resection may participate 
in ssDNA exposure. As characterized during DSB 
processing and repair, when ssDNA regions reach a 
critical size, the recombinase RAD51 partially replaces 
RPA at uncoupled forks, possibly assisted by cofactors 
belonging to the homologous recombination (HR) and 
Fanconi anemia (FA) pathways. RAD51-mediated 
template reannealing primes replication fork reversal, 
probably in concert with yet-unidentified specialized 
enzymatic activities, assisting template repair and lim-
iting nucleolytic degradation of nascent strands upon 
prolonged stalling. PARP activation at discontinuous 
nascent strands and/or regressed arms stabilizes the 
forks in the reversed state, by transiently inhibiting 
the specific restart activity of RECQ1 helicase until the 
damage is repaired or the stress is released. RAD51 
loading on regressed arms may further protect forks after 
reversal and promote alternative homology-mediated 
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Drugs and reagents
CPT (Sigma-Aldrich) and cis-diammineplatinum(II)dichloride (Sigma- 
Aldrich) were dissolved in DMSO to yield a 20-mM (7 mg/ml) and a 15-mM 
(4.5 mg/ml) stock, respectively (freshly made). ETP (Sigma-Aldrich) and 
DOX (Sigma-Aldrich) were dissolved in DMSO to a stock concentration of 
10 mM (6 mg/ml) and 5 mM, respectively, with aliquots stored at 4°C, 
protected from light. APH (Sigma-Aldrich) was dissolved in DMSO to yield 
a 3-mM stock, and aliquots were stored at 20°C. HU (Sigma-Aldrich) 
and MMC (Sigma-Aldrich) were prepared in double-distilled H2O to obtain 
a 100-mM (7.6 mg/ml) and a 3-mM (1 mg/ml) stock (freshly made), 
respectively. MMS purchased as a 10-M solution was stored at 4°C. 
Hydrogen peroxide solution (H2O2) 35% by weight in H2O (Sigma-Aldrich) 
was dissolved in double-distilled H2O. UV irradiation was administered 
using a UV 254-nm lamp.
Cell cycle analysis
Asynchronous subconfluent cultures of U2OS cells were treated with the 
indicated dose of the genotoxic agents for 8, 24, and 48 h. Time point 0 h 
represents cell cycle distribution of nontreated cells. The cells were then 
trypsinized, collected, and spun down at 400 g for 5 min (using 12 × 
75–mm falcon tubes). The cells were washed with 1–2 ml PBS and spun 
down at 400 g for 5 min. After discarding PBS, control and treated cells 
were fixed with 70% ethanol at 4°C (for ≥30 min), washed, digested with 
100 µg/ml RNase A, stained with 25 µg/ml propidium iodide, subjected 
to flow microfluorimetry on a flow cytometer (FACScan; BD), and analyzed 
by the FlowJo software (Tree Star). Flow cytometric analysis for G-H2AX/
EdU/DAPI, cells were labeled for 30 min with 10 µM EdU, harvested, and 
fixed for 10 min with 4% formaldehyde/PBS. Cells were washed with 1% 
BSA/PBS, pH 7.4, permeabilized with 0.5% saponin/1% BSA/PBS, and 
stained with mouse anti–G-H2AX antibody (05-636; EMD Millipore) for 2 h 
followed by incubation with a suitable secondary antibody for 30 min. 
Incorporated EdU was labeled according to the manufacturer’s instructions 
(Invitrogen). DNA was stained with 1 µg/ml DAPI. Samples were mea-
sured on a flow cytometer (CyAn ADP; Beckman Coulter) and analyzed 
with Summit software v4.3 (Beckman Coulter).
Immunofluorescence microscopy
Cells were grown on coverslips in 10 µM BrdU for 48 h before the treat-
ment with drugs. Cells were then treated with the aforementioned drugs for 
1 h. After treatment, cells were washed with PBS and preextracted (25 mM 
Hepes, pH 7.4, 50 mM NaCl, 1 mM EDTA, 3 mM MgCl2, 300 mM sucrose, 
and 0.5% Triton X-100) on ice. Cells were then fixed using 4% formaldehyde 
for 15 min at RT. Fixed cells were then incubated with primary antibodies 
against BrdU mouse (347580; BD) and G-H2AX rabbit (9718; Cell Signal-
ing Technology) in a moist chamber for 1 h. Cells were incubated with sec-
ondary antibodies (anti–mouse 488 [A11029; Invitrogen] and anti–rabbit 
594 [A11037; Invitrogen]) in a moist chamber for 1 h. For RAD51 and EdU, 
coverslips were preextracted in preextraction buffer (80 mM NaCl and 
3 mM MgCl2) and fixed with 4% paraformaldehyde in PBS followed by 
permeabilization with 0.5% Triton X-100 in PBS. Subsequently, Click-iT 
reaction was performed using the manufacturer’s protocol (Invitrogen). Next, 
cells were blocked in 1% BSA and incubated with primary antibody against 
RAD51 rabbit (gift from F. Esashi, Sir William Dunn School of Pathology, 
University of Oxford, Oxford, England, UK) in a moist chamber. Coverslips 
were then incubated with secondary antibody (anti–rabbit 594; A11037). 
Coverslips were then washed with PBS, mounted with 4 µl Vectashield/
DAPI, and sealed with nail polish. Cells were washed between all steps.
Microscopy was performed with a fluorescence microscope (DMRB; 
Leica; objective lenses: HCX Plan Apochromat 63×/1.40-0.60 NA oil) 
and acquired with a camera (DFC 360FX; Leica). The images were pro-
cessed with Leica Application Suite Version 3.3.0.
Cell proliferation and viability
CellTiter blue reagent was used to estimate the number of viable cells pres-
ent in multiwell plates after treating 2,000 cells/well with the doses of the 
genotoxic agents indicated in Fig. S1. 20 µl of CellTiter blue reagent was 
added to 100 µl of medium in the 96-well plate followed by incubation for 
3 h at 37°C. The fluorescent signal was measured by recording fluores-
cence (560 nm(20)Ex/590 nm(10)Em) using a plate reader (Fluoroskan As-
cent; Labsystems).
Human fork progression by DNA fiber analysis
The procedure was essentially performed according to Jackson and Pombo 
(1998), with previously described modifications (Ray Chaudhuri et al., 
2012). In brief, asynchronously growing U2OS cells were labeled with 
It will also be important to identify specific enzymatic 
activities required to assist RAD51 in driving replication fork 
reversal in vivo (Fig. 8; Neelsen and Lopes, 2015), presumably 
included in the list of factors showing fork remodeling activity 
in vitro (Kanagaraj et al., 2006; Machwe et al., 2006; Ralf et al., 
2006; Gari et al., 2008; Blastyák et al., 2010; Bugreev et al., 
2011; Bétous et al., 2012, 2013; Ciccia et al., 2012; Burkovics 
et al., 2014). Conversely, in light of our data, it will be important 
to extend the limited information on how the addition of RAD51 
and RPA in the reactions may impact the biochemical proper-
ties of these fork remodeling proteins (Kanagaraj et al., 2006; 
Bugreev et al., 2011; Bétous et al., 2013; Burkovics et al., 2014).
Although we propose that the observed nascent strand 
degradation upon HR defects (Schlacher et al., 2011) is primar-
ily a consequence of defective fork reversal upon prolonged 
fork stalling, our data do not exclude an additional role of 
RAD51 in stabilizing reversed forks during prolonged replica-
tion stress—as originally proposed (Schlacher et al., 2011)—by 
protecting the regressed arms from unscheduled nucleolytic 
attacks and assisting homology-directed fork restart (Fig. 8). It 
should be noted, however, that controlled regressed arm resec-
tion, which contributes to fork restart upon prolonged fork stall-
ing, is genetically distinct from the extensive nascent strand 
degradation observed upon HR/FA defects (Schlacher et al., 
2011; see Thangavel et al., in this issue).
Impairment of replication fork reversal may contribute 
to explain the potentiating effects of PARP inhibitors on sev-
eral chemotherapeutic treatments (Rouleau et al., 2010; Ray 
Chaudhuri et al., 2012) and may also provide alternative mecha-
nistic explanations for the observed synthetic lethality of PARP 
inhibition and HR defects (Farmer et al., 2005; Neelsen and 
Lopes, 2015). By analogy, the search for biochemical activities 
specifically required for fork reversal in vivo holds great poten-
tial to identify novel targets to potentiate cancer chemotherapy 
based on replication interference.
Materials and methods
Cells and cell culture
Human osteosarcoma U2OS cells, RPE-1 cells, or HEK293T cells were cul-
tured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 
100 µg/ml streptomycin in an atmosphere containing 6% CO2 at 37°C. 
Cells were treated with different cancer chemotherapeutics and DNA- 
damaging agents as indicated, trypsinized, and processed for cell cycle 
analysis, Western blots, PFGE, and EM DNA extraction.
Genetic inactivation by sh/siRNA
shRNA-mediated down-regulation was achieved by cloning the sequence 
targeting RECQ1 (5-GAGCTTATGTTACCAGTTA-3) into the pLKO.1 
(plasmid #10878; Addgene) lentiviral shRNA expression vector. Lentiviral 
particles were generated by transient cotransfection of pLKO.1 and the 
packaging plasmids psPAX2 (plasmid #12260; Addgene) and pM2D.G 
(plasmid #12259; Addgene) into HEK293T cells. Viral supernatants were 
filtered through a 0.45-µM filter and transduced on U2OS cells for 24 h 
followed by selection with 8 µg/ml puromycin for 3 d. Control transductions 
were performed using the pLKO.1 vector expressing a shRNA targeting 
Luciferase (5-ACGCTGAGTACTTCGAAATGT-3). For siRNA experiments, 
cells were transfected with the indicated siRNA using RNAiMAX (Invitrogen) 
according to manufacturer’s instruction. The experiments were performed 
24 or 72 h after transfection. Purchased sequences were as follows: Luc 
siRNA (40 nM; 5-CGUACGCGGAAUACUUCGA-3), RAD51 #1 siRNA 







Published March 2, 2015
116
577Rad51 mediates fork reversal upon genotoxic stress • Zellweger et al.
IgG and horseradish peroxidase–linked whole antibody from sheep (GE 
Healthcare). The membrane was then exposed to an ECL system (detection 
reagent final volume equivalent to 0.125-ml/cm2 membrane; GE Health-
care), and a charge-coupled device image analyzer was used to visualize 
immunoreactive bands.
EM analysis of DNA RIs in human cells
The procedure was essentially performed as previously described 
(Neelsen et al., 2014). Asynchronous subconfluent cultures of U2OS cells 
were treated with defined doses of the genotoxic agents for 1 h. In vivo 
psoralen cross-linking of the DNA was achieved by a repetitive exposure 
of living cells to 4,5,8-trimethylpsoralen (10 µg/ml final concentration) 
followed by irradiation pulses with UV 365-nm monochromatic light (UV 
Stratalinker 1800; Agilent Technologies). The cells were then lysed with 
cell lysis buffer (buffer C1: 1.28 M sucrose, 40 mM Tris-Cl, pH 7.5, 
20 mM MgCl2, and 4% Triton X-100; QIAGEN) and then digested by 
digestion buffer (QIAGEN buffer G2: 800 mM guanidine–HCl, 30 mM 
Tris–HCl, pH 8.0, 30 mM EDTA, pH 8.0, 5% Tween 20, and 0.5% Triton 
X-100) and 1 mg/ml proteinase K at 50°C for 2 h. Chloroform/Isoamyl 
alcohol (24:1) was used to collect DNA via phase separation (centrifuga-
tion at 8,000 rpm for 20 min) followed by DNA precipitation by adding 
0.7× volume of isopropanol. The DNA was then washed with 70% etha-
nol, air dried, and resuspended in 200 µl TE (Tris-EDTA) buffer. 100 U 
restriction enzyme PvuII high-fidelity was used for 12 µg mammalian 
genomic DNA digestion (4–5-h incubation). Poly-Prep chromatography 
columns were used for RI enrichment. Benzoylated naphthoylated DEAE–
cellulose granules were resuspended in 10 mM Tris-HCl, pH 8.0, and 
300 mM NaCl to a final concentration of 0.1 g/ml. The columns were 
washed and equilibrated with 10 mM Tris-HCl, pH 8.0, and 1 M NaCl 
and 10 mM Tris-HCl, pH 8.0, and 300 mM NaCl, respectively. The 
sample DNA was then loaded and incubated for 0.5 h. After washing 
the columns (10 mM Tris-HCl, pH 8.0, and 1 M NaCl), the DNA was 
eluted in caffeine solution (10 mM Tris-HCl, pH 8.0, 1 M NaCl, and 
1.8% [wt/vol] caffeine) for 10 min followed by sample collection. DNA is then 
purified and concentrated, using an Amicon size-exclusion column and 
resuspended in TE. With DNA spreading by the “BAC method,” the DNA 
was loaded on carbon-coated 400-mesh copper grids. The DNA was 
then coated with platinum by platinum-carbon rotary shadowing (High 
Vacuum Evaporator MED 020; Bal-Tec). Microscopy was performed with 
a transmission electron microscope (Tecnai G2 Spirit; FEI; LaB6 filament; 
high tension ≤120 kV) and acquired with a side mount charge-coupled 
device camera (2,600 × 4,000 pixels; Orius 1000; Gatan, Inc.). The im-
ages were processed with DigitalMicrograph Version 1.83.842 (Gatan, 
Inc.) and analyzed with ImageJ (National Institutes of Health).
iPOND
iPOND was essentially performed as originally described (Sirbu et al., 
2011, 2012) with minor modifications. HEK293T cells were labeled with 
10 µM EdU (Life Technologies) and treated with the different drugs as indi-
cated. For the pulse-chase experiments with thymidine, cells were washed 
with cell culture medium and incubated for 45 min in medium supple-
mented with 10 µM thymidine (Sigma-Aldrich). Then, the cells were cross-
linked with 1% formaldehyde for 15 min at RT, quenched with 0.125 M 
glycine for 5 min, and washed three times with PBS. For the conjugation 
of EdU with biotin azide, cells were permeabilized with 0.25% Triton 
X-100/PBS, washed twice with PBS, and incubated in click reaction buffer 
(10 mM sodium-L-ascorbate, 20 µM biotin azide [Life Technologies], and 
2 mM CuSO4) for 1 h at RT. DMSO was used instead of biotin azide for 
the “no click” control. Cells were washed twice with PBS, resuspended in 
lysis buffer (50 mM Tris-HCl, pH 8.0, and 1% SDS) supplemented with 
protease inhibitors (Sigma-Aldrich), and chromatin was solubilized by soni-
cation in a Bioruptor (Diagenode) at 4°C at the highest setting for 10 min 
(30 s on and 45 s off cycles). After centrifugation for 30 min at 14,000 
rpm, supernatants were diluted with 1:1 PBS (vol/vol) containing prote-
ase inhibitors and incubated overnight with streptavidin-agarose beads 
(EMD Millipore). Beads were washed once with lysis buffer, once with 
1 M NaCl, twice with lysis buffer, and once with PBS, and captured 
proteins were eluted by boiling beads in 2× NuPAGE LDS Sample Buffer 
(Life Technologies) containing 100 mM DTT for 30 min at 95°C. Proteins were 
resolved by electrophoresis using NuPAGE Novex 4–12% Bis-Tris gels and 
detected by Western blotting with the indicated antibodies: RAD51 rab-
bit polyclonal (1:1,000; H92; Sigma-Aldrich), proliferating cell nuclear 
antigen mouse monoclonal (F2; 1:2,000; Sigma-Aldrich), RPA32 mouse 
monoclonal (NA19L; 1:1,000; EMD Millipore), RPA32-S4/S8 rabbit poly-
clonal (A300-245A; 1:1,000; Bethyl Laboratories), G-H2AX–S139 rabbit 
30 µM chlorodeoxyuridine (CldU; Sigma-Aldrich), a thymidine analogue, 
for 30 min, washed twice with PBS, treated with appropriate dosage with 
any of the genotoxic agents (or nontreated as control), and exposed to 
250 µM 5-iodo-2-deoxyuridine (IdU). The cells were quickly trypsinized 
and resuspended in PBS at 2.5 × 105 cells/ml. The labeled cells were 
diluted 1:8 with unlabeled cells, and 2.5 µl of cells were mixed with 7.5 µl 
of lysis buffer (200 mM Tris-HCl, pH 7.5, 50 mM EDTA, and 0.5% [wt/vol] 
SDS) on a glass slide. After 9 min, the slides were tilted at 15–45°, and 
the resulting DNA spreads were air dried, fixed in 3:1 methanol/acetic 
acid, and refrigerated overnight. The DNA fibers were denatured with 
2.5 M HCl for 1 h, washed with PBS, and blocked with 2% BSA in PBST 
(PBS and Tween 20) for 40 min. The newly replicated CldU and IdU tracks 
were labeled (for 2.5 h in the dark, at RT) with anti-BrdU antibodies recog-
nizing CldU (rat; Abcam) and IdU mouse (BD), respectively. After washing 
for 5 × 3 min in PBST (0.2%), the following secondary antibodies were 
used (incubated for 1 h in the dark, at RT): anti–mouse Alexa Fluor 488 
(Molecular Probes) and anti–rat Cy3 (Jackson ImmunoResearch Labora-
tories, Inc.). After washing for 5 × 3 min in PBST (0.2%), the slides were 
air dried completely, mounted with 20 µl/slide Antifade gold (Invitrogen), 
and sealed to a coverslip by transparent nail polish. Microscopy was per-
formed with a fluorescence microscope (IX81; Olympus; objective lenses: 
LC Plan Fluor 60×, 1.42 NA oil) and acquired with a charge-coupled 
device camera (Orca AG; Hamamatsu Photonics). The images were pro-
cessed with CellR software (version2.6; Olympus). Statistical analysis of 
track length was performed using Prism (GraphPad Software). The signifi-
cance of the difference between the means was determined by t test or by 
one-way analysis of variance (ANOVA).
DSB detection by PFGE
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Vujanovic et al. show that UBC13-
mediated, K63-linked PCNA
polyubiquitination mediates DNA
damage-induced replication fork slowing
and reversal, via recruitment to forks of
ZRANB3 DNA translocase. These data
link the postreplication repair pathway,
yet elusive in mammals, to the regulation
of fork progression and remodeling.
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DNA damage tolerance during eukaryotic replication
is orchestrated by PCNA ubiquitination. While mono-
ubiquitination activates mutagenic translesion syn-
thesis, polyubiquitination activates an error-free
pathway, elusive in mammals, enabling damage
bypass by template switching. Fork reversal is driven
in vitro bymultiple enzymes, including the DNA trans-
locase ZRANB3, shown to bind polyubiquitinated
PCNA. However, whether this interaction promotes
fork remodeling and template switching in vivo was
unknown. Here we show that damage-induced fork
reversal in mammalian cells requires PCNA ubiquiti-
nation, UBC13, and K63-linked polyubiquitin chains,
previously involved in error-free damage tolerance.
Fork reversal in vivo also requires ZRANB3 translo-
case activity and its interaction with polyubiquiti-
nated PCNA, pinpointing ZRANB3 as a key effector
of error-free DNA damage tolerance. Mutations
affecting fork reversal also induced unrestrained
fork progression and chromosomal breakage, sug-
gesting fork remodeling as a global fork slowing
and protectionmechanism. Targeting these fork pro-
tection systems represents a promising strategy to
potentiate cancer chemotherapy.
INTRODUCTION
Replicating cells react to genotoxic stress activating different
molecular pathways, devoted to regulate origin firing and to pro-
tect the stability of ongoing replication forks (Berti and Vindigni,
2016). Replication completion in the presence of DNA lesions is
assisted by the activation of the so-called ‘‘post-replication
repair’’ (PRR) pathway, which is modulated in eukaryotic cells
by controlled ubiquitination of the DNA polymerase clamp, i.e.,
proliferating cellular nuclear antigen (PCNA) (Branzei and Psa-
khye, 2016; Garcı´a-Rodrı´guez et al., 2016). Accumulation of sin-
gle-stranded DNA (ssDNA) at replication forks facing DNA le-
sions triggers recruitment of the E2-E3 pair RAD6-RAD18,
mediating PCNA mono-ubiquitination on the K164 residue
(Hoege et al., 2002; Niimi et al., 2008). This modification has
been linked to the recruitment of translesion synthesis (TLS)
polymerases, promoting error-prone DNA damage bypass at
the expense of increased mutations rates (Bienko et al., 2005;
Plosky et al., 2006). In yeast, further modification of the same
PCNA residue via K63-linked polyubiquitination—which requires
the dimeric E2 MMS2/UBC13 and the Rad5 E3 ligase (Hoege
et al., 2002)—promotes error-free PRR, an alternative DNA dam-
age tolerance pathway that fills postreplicative ssDNA gaps via
template-switching (TS) and recombinational mechanisms,
involving sister chromatid junctions (Branzei and Psakhye,
2016; Giannattasio et al., 2014). Alternative models for error-
free PRR and TS entail remodeling of the replication fork in a
four-way junction—a process known as replication fork
reversal—to allow TS to occur directly at the elongating fork (Hig-
gins et al., 1976). However, replication fork reversal in yeast cells
has only been observed upon fork stalling in replication or check-
point mutants (Fumasoni et al., 2015; Sogo et al., 2002) or upon
topological stress induced by Topoisomerase I (Top1) poisons
(Ray Chaudhuri et al., 2012), questioning the physiological role
of fork reversal in this organism.
In mammals, detection of PCNA polyubiquitination proved
more difficult and has so far required acute genotoxic treatments
and/or overexpression of the responsible enzymes (Brun et al.,
2010; Motegi et al., 2008). Rad5 has two related proteins in hu-
man cells—HLTF and SHPRH—both contributing to PCNA poly-
ubiquitination (Motegi et al., 2008; Unk et al., 2010), possibly as-
sisting the response to different types of DNA damage (Lin et al.,
2011). A third E3 ligase has also been invoked (Krijger et al.,
2011). Whether PCNA polyubiquitination directly promotes TS
and/or regulates TLS has long been controversial (Garcı´a-Rodrı´-
guez et al., 2016). Also, no direct data are currently available on
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whether error-free PRR in higher eukaryotes mostly entails post-
replicative junctions or fork reversal. Intriguingly, besides their E3
ligase activity, both Rad5 in yeast and HLTF in human cells
possess specific domains capable of reversing replication forks
in vitro (Blastya´k et al., 2007; Kile et al., 2015), although their
contribution to fork reversal in vivo is currently uncertain.
Recent visual inspection of mammalian replication intermedi-
ates in vivo has uncovered replication fork reversal as a global
and genetically controlled response to various challenges to
the replication process. These include oncogene activation, un-
stable repetitive sequences, and treatments with various geno-
toxins (Follonier et al., 2013; Neelsen et al., 2013; Ray Chaudhuri
et al., 2012; Zellweger et al., 2015). These transient structures
were proposed to exert a protective role upon replication stress,
but to date only a few factors have been directly implicated in
their formation, stabilization, and restart (Neelsen and Lopes,
2015). Importantly, genetic defects in reversed fork formation
or stabilization upon genotoxic treatments were also shown to
impair active replication fork slowing, thus linking controlled
fork progression and fork remodeling upon replication stress
(Ray Chaudhuri et al., 2012; Zellweger et al., 2015). PCNA ubiq-
uitination was shown to be dispensable for continued fork pro-
gression upon UV damage in DT40 cells (Edmunds et al.,
2008), but its potential contribution to actively remodel and
slow down replication forks in mammalian cells has not been
thoroughly investigated.
A number of proteins, mostly belonging to RECQ helicase or
SWI/SNF protein families, are able to reverse forks in biochem-
ical assays (Neelsen and Lopes, 2015). HARP/SMARCAL1 and
AH2/ZRANB3 DNA translocases can re-anneal RPA-coated
DNA strands (Yusufzai and Kadonaga, 2008, 2010) and reverse
synthetic replication forks (Be´tous et al., 2012, 2013; Ciccia
et al., 2012), but their contribution to fork reversal in vivo is
elusive. ZRANB3 was shown to associate with replication fac-
tories, to assist restart of stalled forks and to mildly contribute
to genotoxin resistance (Ciccia et al., 2012; Yuan et al., 2012).
These functions require the DNA translocase activity of ZRANB3,
as well as its binding to PCNA—via PIP and APIM domains—and
to polyubiquitinated PCNA—via its NZF domain (Ciccia et al.,
2012; Yuan et al., 2012). ZRANB3 carries also a structure-spe-
cific endonuclease activity in the HNH domain (Weston et al.,
2012), but its functional relevance is currently unclear.
Here, combining DNA fiber analysis and electron microscopy
(EM) visualization of replication intermediates in vivo, we provide
evidence that PCNA polyubiquitination mediates active fork
slowing and reversal upon genotoxic treatments. Moreover, we
report that a known ‘‘reader’’ of this modification—the translo-
case ZRANB3—regulates fork speed, fork remodeling, and
chromosome integrity in vivo, via its DNA translocase activity
and its ability to interact with polyubiquitinated PCNA.
RESULTS
PCNA Ubiquitination Mediates Active Fork Slowing and
Reversal upon Genotoxic Stress
In order to assess whether PCNA ubiquitination is required to
actively reduce replication fork speed upon replication stress,
we investigated by DNA fiber spreading replication fork progres-
sion in PCNA-K164R mouse embryonic fibroblasts (MEFs) and
their wild-type counterparts (Langerak et al., 2007). We com-
bined incorporation of halogenated nucleotides and optional
treatments with nanomolar doses of the Top1 inhibitor campto-
thecin (CPT) or the DNA crosslinking agent mitomycin C (MMC)
(Zellweger et al., 2015). Both treatments induced a significant
slowdown of replication fork progression, but this response
was abolished by the K164R PCNA mutation (Figures 1A and
1B). Thus, PCNA ubiquitination is strictly required to mediate
active fork slowing upon these genotoxic treatments.
We next used psoralen crosslinking coupled to EM (Zellweger
and Lopes, 2017) to investigate in vivo replication fork archi-
tecture and to reveal the possible conversion of standard repli-
cation forks into four-way junctions—known as reversed forks
(Figure 1C)—previously associated with a variety of genotoxic
treatments (Ray Chaudhuri et al., 2012; Zellweger et al., 2015).
As expected, reversed fork frequency in wild-type MEFs
was markedly increased by CPT and MMC treatments. Remark-
ably, PCNA-K164R MEFs did not significantly increase
reversed fork levels upon both genotoxic treatments (Figure 1D,
Table S1A), showing that PCNA ubiquitination is required for
effective replication fork reversal. Similar DNA fiber and EM
results were obtained upon CPT treatment in independent lines
of wild-type and PCNA-K164R MEFs (Figures S1A and S1B,
Table S1B).
In order to visualize endogenous PCNA modifications occur-
ring upon different genotoxic treatments, we performed cell frac-
tionation to enrich for polyubiquitinated species of PCNA (Fig-
ure S1C). This approach enabled us to detect endogenous
levels of polyubiquitinated PCNA, which were induced upon
acute UV irradiation (Figure S1D), as previously reported (Motegi
et al., 2008). Albeit technically challenging, using this protocol we
detected low levels of polyubiquitinated PCNA also upon nano-
molar doses of CPT or MMC, as those typically used for our DNA
fiber and EM experiments (Figure S1D).
K63-Linked, UBC13-Dependent Polyubiquitination Is
Required for Fork Slowing and Reversal upon Genotoxic
Stress
In order to distinguish whether PCNA mono- or poly-ubiquitina-
tion mediates the observed fork slowing and reversal upon gen-
otoxic stress, we took advantage of a previously characterized
ubiquitin replacement system in U2OS cells (Xu et al., 2009).
Doxycycline addition allows the replacement of endogenous
ubiquitin with similar levels of exogenous wild-type or K63R
mutant ubiquitin and does not impair overall cell-cycle progres-
sion (Figures S2A and S2B). DNA fiber experiments revealed that
impairing K63-linked ubiquitin chain formation by the K63R mu-
tation significantly affects CPT-induced replication fork slowing
(Figure 2A). Moreover, replacement of endogenous ubiquitin
with the K63R mutant markedly reduced the frequency of fork
reversal upon CPT and MMC treatment (Figure 2B, Table S2A).
Thus, K63-linked polyubiquitination is essential for efficient fork
remodeling upon genotoxic stress.
In light of the reported redundancy of different E3 ligases
mediating PCNA polyubiquitination (Krijger et al., 2011; Motegi
et al., 2008), we next assessed the relevance of PCNA poly-
ubiquitination by inactivation of the E2 enzyme required for
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this modification, i.e., UBC13 (Garcı´a-Rodrı´guez et al., 2016).
UBC13 knockout (KO) in HCT116 cells did not affect cell-cycle
progression (Figure S2C) but abolished the reduction in replica-
tion fork speed upon CPT, MMC, and UV-C treatments (Figures
2C and 2D). Moreover, UBC13-KO cells failed to appreciably
induce replication fork reversal, monitored by EM, upon all
tested genotoxic treatments (Figure 2E; Table S2B). Similar re-
sults were obtained by siRNA-mediated downregulation of
Figure 1. PCNA Ubiquitination Is Required
for Replication Fork Slowing and Reversal
upon Genotoxic Stress
(A) Labeling scheme of DNA fiber experiments:
cells were provided with chlorodeoxyuridine (CldU,
red). 30 min later, cells were washed and supple-
mented with iododeoxyuridine (IdU, green) and
optionally treated with camptothecin (CPT) 50 nM
and/or mitomycin C (MMC) 200 nM for 30 min.
Green tracks were measured to assess fork speed.
(B) Control and PCNA-K164R mouse embryonic
fibroblasts (MEFs) were subjected to the DNA fiber
protocol described in (A). At least one hundred
tracts were scored per sample.Whiskers: 10th–90th
percentile (***p < 0.001; ns, non-significant; Mann-
Whitney test). Similar results were obtained in at
least two biological replicates.
(C) Representative electron microscopy images of
reversed (left) or normal (right) replication forks. P, pa-
rental strand; D, daughter strand; R, regressed arm.
(D) Frequency of reversed forks in the indicated
MEFs, upon optional 1 hr treatment with CPT
50 nM or MMC 200 nM, assessed by EM visuali-
zation. Similar results were obtained in two bio-
logical replicates and in independent MEF clones
(Tables S1A and S1B).
UBC13 in CPT- or MMC-treated U2OS
cells (Figures S2D–S2F, Table S2C).
Taken together, the data presented so
far strongly suggest that PCNA poly-
ubiquitination is required to mediate
active fork slowing and fork reversal
upon different genotoxic treatments.
The ZRANB3 Translocase Is
Required for Fork Slowing and
Reversal upon Different Genotoxic
Treatments
As the DNA translocase ZRANB3 was
reported as a specific interactor of
polyubiquitinated PCNA and was shown
to mediate replication fork reversal in
biochemical assays (Ciccia et al., 2012),
we directly tested its requirement for repli-
cation fork slowing and reversal in vivo.
Therefore, a ZRANB3 knockout U2OS
cell line generated by CRISPR/Cas9 tech-
nology—which did not display altered
cell-cycle progression (Figure S3A)—was
compared to its wild-type counterpart
for replication fork slowing by DNA fiber assays and for fork
reversal by EM, upon treatment with CPT, MMC, and UV-C. As
observed upon impairment of UBC13-dependent K63-linked
polyubiquitination (Figure 2), ZRANB3-KO cells displayed unre-
strained fork progression in response to all tested treatments,
with fork slowing being completely abolished upon CPT, MMC,
and UV treatments (Figures 3A and 3B). Moreover, ZRANB3-
KO cells displayed unaffected frequencies of fork reversal in
884 Molecular Cell 67, 882–890, September 7, 2017
127
unperturbed conditions but were unable to efficiently promote
replication fork reversal upon all tested genotoxic treatments
(Figure 3C, Table S3A). Similar effects were observed by DNA fi-
ber spreading and EM analysis of another ZRANB3-KO clone
and upon siRNA-mediated downregulation of ZRANB3 in
U2OS cells (Figures S3A–S3F, Tables S3B and S3C).
Damage-Induced Fork Slowing and Reversal Protect
Chromosome Integrity and Require ZRANB3-PCNA
Interaction and ZRANB3 DNA Translocase Activity
ZRANB3 contains multiple domains and motifs, which mediate
its enzymatic activities or the interaction with PCNA and its ubiq-
Figure 2. K63-Linked, UBC13-Dependent
Polyubiquitination Is Required for Drug-
Induced Fork Slowing and Reversal
(A) Cells conditionally (+Dox) replacing endoge-
nous ubiquitin with a K63R ubiquitin mutant were
subjected to the DNA fiber protocol as in Figure 1A.
The ratio between green and red tracts is plotted,
to display drug-induced fork slowing.
(B) Frequency of replication fork reversal in cells
replacing endogenous ubiquitin with WT or K63R-
ubiquitin, upon optional 1 hr treatment with CPT
50 nM or MMC 200 nM, assessed by EM visuali-
zation. In brackets, the number of analyzed mole-
cules. Similar results were obtained in two biolog-
ical replicates (Table S2A).
(C) Wild-type (WT) or UBC13-knockout (UBC13-
KO) HCT116 cells were subjected to the DNA fiber
protocol in Figure 1A.
(D) The same cell lines as in (C) were used for DNA
fiber analysis, upon optional 5 J/m2 UV-C irradia-
tion in between the two labeling periods. Top right:
the western blot shows the absence of UBC13 in
UBC13-KO HCT116 cells. GAPDH, loading con-
trol. In (A), (C), and (D) at least one hundred tracts
were scored per sample. Whiskers: 10th–90th
percentile (****p < 0.0001; ***p < 0.001; ns, non-
significant; Mann-Whitney test). Similar results
were obtained in at least two biological replicates.
(E) Frequency of replication fork reversal in WT and
UBC13-KO HCT116 cells, assessed by EM visu-
alization, upon optional 1 hr treatment with CPT
50 nM or MMC 200 nM, or 1 hr after 5 J/m2 UV-C
irradiation. In brackets, the number of analyzed
molecules. Similar results were obtained in two
biological replicates (Table S2B).
uitinated forms (Ciccia et al., 2012;
Weston et al., 2012; Yuan et al., 2012).
To assess the relevance of these activities
and interactions in replication fork slowing
and reversal in vivo, we analyzed specific
point mutations in ZRANB3 (Figure 4A),
affecting respectively its interaction with
PCNA (PIP+APIM domains), its interac-
tion with polyubiquitinated PCNA (NZF-
zinc finger), its DNA translocase activity
(DEXDc domain; helicase dead [HD]) (Cic-
cia et al., 2012), or a crucial residue of the
HNH domain, which was shown to pro-
vide ZRANB3 nuclease activity (Weston et al., 2012). We ob-
tained stable cell lines by viral transduction of ZRANB3-KO
U2OS cells, re-expressing FLAG/HA-tagged wild-type ZRANB3
or one of these mutant forms. We ensured that all tagged pro-
teins were expressed at approximately the level of endogenous
ZRANB3 in the original U2OS cell line (Figure 4A) and that none of
the mutant cell lines hadmarked delays in cell-cycle progression
(Figure S4A). Using these cell lines, we assessed whether wild-
type and mutant forms of ZRANB3 could complement the de-
fects in fork slowing and reversal observed in ZRANB3-KO cells
(Figure 3), focusing on CPT treatments. Expression of WT
ZRANB3 in ZRANB3-KO cells restored effective CPT-induced
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fork slowing and reversal (Figures 4B and 4C, Table S4), showing
that the tagged protein is functional upon genotoxic treatment.
Expression of the PIP+APIMmutant failed to restore fork slowing
and reversal, suggesting that ZRANB3-PCNA interaction is
essential to regulate fork progression and remodeling upon dam-
age. Similarly, mutations destabilizing the NZF zinc finger
impaired CPT-induced fork slowing and reversal (Figures 4B
and 4C, Table S4). A complete defect in fork slowing and reversal
was also observed upon expression of the helicase dead (HD)
mutant that impairs ZRANB3 DNA translocation activity, while
a mutant that inactivates the HNH nuclease motif restored effi-
cient control of fork progression and remodeling (Figures 4B
and 4C, Table S4). Thus, effective interaction of ZRANB3 with
both unmodified and polyubiquitinated PCNA and its DNA trans-
locase activity, but not an intact HNH nuclease domain, are
required for replication fork slowing and reversal upon genotoxic
stress. In order to test whether ZRANB3-mediated fork slowing
and reversal limit DNA damage-induced chromosomal insta-
bility, we assessed chromosomal abnormalities by metaphase
spreads after CPT treatment. To exclude selection of compensa-
tory mutations in ZRANB3-KO cells, we chose to transiently
inactivate ZRANB3 by siRNA in cell lines stably expressing
siRNA-resistant HA-tagged ZRANB3 variants that retain (WT,
HNH) or impair (PIP-APIM) fork slowing and reversal activities
(Figures 4A–4C; Figure S4B). ZRANB3 downregulation led to
Figure 3. ZRANB3 Is Required for Efficient
Replication Fork Slowdown and Fork
Reversal upon Different Genotoxic Treat-
ments
(A) Wild-type (WT) or ZRANB3-knockout
(ZRANB3-KO) U2OS cells were subjected to the
DNA fiber protocol as in Figure 1A.
(B) The same cell lines as in (A) were used for DNA
fiber analysis, upon optional 5 J/m2 UV-C irradia-
tion in between the two labelings. Top right: the
western blot shows the absence of ZRANB3 in
ZRANB3-KO U2OS cells. b tubulin, loading con-
trol. In (A) and (B), at least one hundred tracts were
scored per sample. Whiskers: 10th–90th percentile
(****p < 0.0001; ***p < 0.001; **p < 0.01; *p < 0.1; ns,
non-significant; Mann-Whitney test). Similar re-
sults were obtained in at least two biological
replicates.
(C) Frequency of replication fork reversal inWT and
ZRANB3-KO U2OS cells, assessed by EM visual-
ization, upon optional 1 hr treatment with CPT
50 nM or MMC 200 nM, or 1 hr after 5 J/m2 UV-C
irradiation irradiation. In brackets, the number of
analyzed molecules are shown. Similar results
were obtained in two biological replicates and in
two independent ZRANB3-KO clones (Tables S3A
and S3B).
increased chromosomal abnormalities
upon CPT treatment (Figure 4D). Notably,
this increase was suppressed by the
presence of WT and HNH mutant forms
of ZRANB3, while the PIP-APIM ZRANB3
mutant—specifically defective in fork
slowing and reversal—failed to restore chromosome integrity af-
ter CPT treatment. These data strongly suggest that ZRANB3-
mediated fork slowing and reversal prevent chromosomal insta-
bility upon genotoxic treatments.
DISCUSSION
Our data establish the genetic dependency of replication fork
slowing and reversal on PCNA ubiquitination, UBC13, and
K63-linked polyubiquitination—all of which are known to
mediate the error-free PRR pathway in mammalian cells (Gar-
cı´a-Rodrı´guez et al., 2016)—thus showing that activation of
this pathway entails global fork slowing and reversal in
response to a variety of genotoxic treatments. In agreement
with the prevalent occurrence of error-free PRR at replication
forks in higher eukaryotes, in human cells we failed to detect
significant accumulation of postreplicative junctions—under
similar experimental conditions that were previously success-
fully used to visualize and characterize TS postreplicative in-
termediates in S. cerevisiae cells (Giannattasio et al., 2014)—
even upon acute treatments and genetic stabilization of these
structures (Figures S4C–S4E). We thus propose that—differ-
ently from yeast cells—activation of the error-free PRR
pathway in human cells leads to extensive fork remodeling,
transiently limiting fork progression on the damaged template.
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In turn, genetic inactivation of fork remodeling in error-free
PRR mutants causes unrestrained fork progression, occasion-
ally leading to chromosomal breaks, visible in the next mitosis.
The choice between fork reversal and postreplicative error-
free PRR likely reflects differences in the efficiency of re-prim-
ing in higher versus lower eukaryotes, the abundance of repet-
itive DNA in human cells and the different control of several
Figure 4. Fork Progression, Fork Remodel-
ing and Chromosomal Integrity Defects
upon Inactivation of Different ZRANB3
Domains
(A) Left: schematic representation of ZRANB3
domain organization and of mutations analyzed in
this study. Right: western blot analysis of ZRANB3
in the indicated cell lines.
(B) The indicated stable cell lines, expressing WT
or mutant ZRANB3, were used for DNA fiber
analysis as in Figure 1A, upon optional CPT 50 nM
treatment. At least one hundred tracts were scored
per sample. Whiskers: 10th–90th percentile (****p <
0.0001; ns, non-significant; Mann-Whitney test).
Similar results were obtained in at least two bio-
logical replicates.
(C) Frequency of replication fork reversal in the
indicated cell lines, assessed by EM visualization,
upon optional 1 hr treatment with CPT 50 nM. In
brackets, the number of analyzed molecules.
Similar results were obtained in two biological
replicates (Table S4).
(D) Left: number of chromosomal abnormalities
per indicated cell line, as determined by meta-
phase spreading upon optional 8 hr CPT treat-
ment (50 nM) and 16 hr nocodazole treatment
(200 ng/mL). Error bars, standard deviations.
Right: representative DAPI stained metaphase; the
arrow points to a chromosome break. Scale bar,
5 mm. Western blot analysis of ZRANB3 protein
levels in U2OS cell lines used in (D, left). In (A) and
(D), the expression level of HA-tagged ZRANB3
WT andmutant proteins (retardedmobility) is close
to endogenous ZRANB3 levels in U2OS cells.
b tubulin, loading control.
key players in these pathways (Branzei
and Psakhye, 2016; Sale, 2012).
By cell fractionation, we were able to
enrich and detect endogenous levels
of polyubiquitinated PCNA upon acute
UV treatment, as previously reported (Mo-
tegi et al., 2008). Albeit technically chal-
lenging (Niimi et al., 2008), in the same
experimental conditions PCNA poly-
ubiquitination could also be detected
upon sublethal (nanomolar) MMC and
CPT treatments. Importantly, while exten-
sive TS is expected at UV-induced
lesions, CPT- and MMC-induced DNA le-
sions are expected to delay template
unwinding and should not extensively
involve DNA damage bypass by TS. We
propose that activation of this branch of
the PRR likely results from a common molecular feature de-
tected at replication forks upon all tested genotoxic treat-
ments—i.e., ssDNA accumulation (Zellweger et al., 2015)—
which reportedly promotes the recruitment of the E3 ligases for
PCNA ubiquitination (Niimi et al., 2008) and may thus mediate
replication fork remodeling even in the absence of a DNA lesion
specifically requiring TS. This scenario is in agreement with the
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surprising evidence that reversed fork frequency in human cells
is not significantly dependent on the type and dose of genotoxic
treatments (Ray Chaudhuri et al., 2012; Zellweger et al., 2015). In
this context, fork reversal should be considered as a general fork
protection mechanism, which actively delays global fork pro-
gression and promotes DNA damage tolerance when required.
The mechanisms underlying the global remodeling of replication
forks from local DNA damage at a subset of forks certainly
deserve further investigation.
In addition, our data uncover the key role in active fork slowing
and reversal of a known interaction partner of polyubiquitinated
PCNA, i.e., the DNA translocase ZRANB3. This protein was
shown to contribute in human cells to genome maintenance
upon genotoxic treatments and to the restart of stalled replica-
tion forks, via its DNA translocase activity and its multiple inter-
actions with unmodified and polyubiquitinated PCNA (Ciccia
et al., 2012; Yuan et al., 2012). Our data reveal the dependency
on the same activity and domains for DNA damage-induced
replication fork slowing and reversal, strongly suggesting that
the key role of ZRANB3 in the replication stress response entails
recruitment to replication forks to assist fork remodeling, in
keeping with its known biochemical properties (Ciccia et al.,
2012). Besides formation of reversed forks, ZRANB3 may also
mediate reversed fork accumulation by controlling their stability,
preventing unscheduled restart or processing. Interestingly,
binding to polyubiquitinated PCNA is not required for ZRANB3
recruitment, but rather for its retention at replication factories
(Ciccia et al., 2012), which may suggest its involvement in modu-
lating fork restart. Our DNA fiber, EM, and chromosomal ana-
lyses of different ZRANB3mutants reinforce the tight association
between fork reversal, active fork slowing, and chromosome sta-
bility in human cells. Inactivation of the ZRANB3 nuclease
domain (HNH) had no visible impact on fork slowing or reversal
and, in keeping with our model, did not increase chromosomal
breakage upon CPT treatment. Alternative mechanistic roles
for ZRANB3 nuclease activity in response to replication stress
will require further investigation.
We noted that the low levels of replication fork reversal consis-
tently observed in unperturbed cells were not significantly
affected by ZRANB3 depletion or inactivation, possibly suggest-
ing that endogenous impediments to fork progression lead to
fork remodeling via ZRANB3-independent mechanisms. How-
ever, this may also reflect the functional redundancy of
other members of the same family—such as SMARCAL1 or
RAD54—possibly providing fork reversal activities when
ZRANB3 is inactive. Similarly, despite the marked reduction in
fork reversal that we observed in ZRANB3-defective cells upon
all tested genotoxic treatments, it is well possible that other
translocases play a role in fork remodeling in response to spe-
cific types of replication interference, as suggested by additive
contributions to cell survival and fork restart upon genotoxic
treatments (Ciccia et al., 2012; Yuan et al., 2012). The functional
analysis of this redundancy and/or damage specificity would
require extensive EM analysis, upon simultaneous inactivation
of several members of this protein family.
As the E3 ligases responsible for PCNA polyubiquitination—
Rad5 in yeast and HLTF, among others, in human cells—were
shown to possess fork reversal activities in biochemical assays
(Blastya´k et al., 2007; Kile et al., 2015), it will be important to
clarify whether these activities stimulate fork reversal in vivo
and how they are possibly coordinated with additional enzymatic
activities recruited to replication forks via binding to polyubiqui-
tinated PCNA (i.e., ZRANB3). Similarly, the central recombinase
RAD51 was shown to mediate fork reversal in vivo (Zellweger
et al., 2015). Understanding the mechanistic cross-talk between
translocase and strand exchange activities in driving fork
reversal will require complex biochemical reconstitution of this
transaction, possibly including chromatinized substrates. More-
over, as additional factors have been proposed to bind polyubi-
quitinated PCNA in yeast and human cells (Saugar et al., 2012), it
will be important to test their potential contribution to fork slow-
ing and reversal upon different genotoxic treatments.
Overall, this study contributes to our mechanistic understand-
ing of active fork slowing and remodeling upon genotoxic treat-
ments. As these fork protection mechanisms are expected to
provide resistance to cancer chemotherapeutic treatments
acting via DNA damage, further elucidation of the underlying
mechanisms will be required to identify promising targets to
potentiate cancer chemotherapy.
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Selective( loss( of( PARG( restores( PARylation( and( counteracts( PARP( inhibitor(
mediated(synthetic(lethality!
This!publication!establishes!that!the!loss!of!poly(ADP6ribose)!glycohydrolase!(PARG)!is!an!important!
mechanism! conferring! PARP! inhibitor! (PARPi)! resistance! in! BRCA2! negative! breast! cancer.! It!
demonstrates!that!PARG!loss!restores!normal!PARylation!levels,!rescues!controlled!replication!fork!
progression!and!promotes!recruitment!of!downstream!DNA!repair!factors!upon!PARPi!treatment.!
However,! PARG! depletion! also! causes! increased! cellular! radiosensitivity,! pointing! towards! an!
opportunity! for!new! therapeutic!approaches! in!PARPi! resistant!breast! cancer.! Furthermore,! the!




moment! values! in! figure! 5B,! demonstrating! that! PARG! inhibition! rescues! controlled! fork!
progression!in!olaparib!and!low!dose!CPT/MMS!treated!cells!and!thereby!alleviates!replication!fork!
breakage.! Moreover,! I! conducted! the! experiment! depicted! in! figure! S5I! showing! that! PARG!
inhibition!also!rescues!controlled!fork!progression!in!cells!treated!with!the!PARP!inhibitor!AZD2461!




Selective Loss of PARG Restores PARylation and




d Endogenous PARG activity is crucial for the success of PARP
inhibition therapy
d PARG suppression restores downstream PARP1 signaling
upon PARP inhibitor treatment
d PARG depletion results in new vulnerabilities that can be
exploited therapeutically
d PARG-negative clones are pre-existing in cancers relevant
for PARPi therapy
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SUMMARY
Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have recently entered the clinic for the treatment of
homologous recombination (HR)-deficient cancers. Despite the success of this approach, drug resistance is
a clinical hurdle, and we poorly understand how cancer cells escape the deadly effects of PARPi without
restoring the HR pathway. By combining genetic screens with multi-omics analysis of matched PARPi-sen-
sitive and -resistant Brca2-mutated mouse mammary tumors, we identified loss of PAR glycohydrolase
(PARG) as a major resistance mechanism. We also found the presence of PARG-negative clones in a subset
of human serous ovarian and triple-negative breast cancers. PARG depletion restores PAR formation and
partially rescues PARP1 signaling. Importantly, PARG inactivation exposes vulnerabilities that can be ex-
ploited therapeutically.
Significance
To explore defects in the DNA damage response in cancer therapy, exciting opportunities have been achieved using the
‘‘synthetic lethal’’ approach. A successful example is the development of PARP inhibitors to kill cancer cells that are defec-
tive in HR; e.g., due to lack of function of BRCA1 or BRCA2. Thus, there is a real opportunity to cure patients with HR-defi-
cient cancers if we overcome the hurdle of drug resistance. At present, it is largely unknown how tumor cells escape PARP
inhibition without restoring BRCA2-mediated HR. Here, we show that loss of PARG governs PARPi resistance in HR-defi-
cient tumors by restoring PARP1 signaling. Importantly, inactivation of PARG results in vulnerabilities that can be exploited
to combat resistance.
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INTRODUCTION
Defects in the DNA damage response (DDR) result in genomic
instability and are implicated in many types of cancer (Dietlein
et al., 2014). DDR alterations are responsible for the accumula-
tion of mutations that result in tumorigenesis, and they can be
specifically exploited for targeted cancer therapy. A prime
example of such a tailored approach is the application of poly
(ADP-ribose) polymerase (PARP) inhibitors (PARPi) in the treat-
ment of tumors defective in homology-directed DNA repair due
to BRCA1 or BRCA2 inactivation (Bryant et al., 2005; Farmer
et al., 2005). PARP1, a founding member of the PARP family,
is a nuclear protein functioning in various cellular processes,
including chromatin remodeling and DNA damage repair
(Gibson and Kraus, 2012). Upon DNA damage, PARP1 is
rapidly recruited to DNA nicks where it induces the synthesis
of protein-conjugated polymers of ADP-ribose (poly(ADP-
ribose) [PAR]). PARP1 itself is a prime target of PARylation
and the resulting PAR chains serve as a platform for the recruit-
ment of downstream repair factors. PARylation is a transient
and reversible modification, as it is counteracted by the activity
of PAR glycohydrolase (PARG), which degrades PAR (Pascal
and Ellenberger, 2015). Inhibition of PARP1 leads to the accu-
mulation of unresolved single-strand breaks (SSBs) (Xu et al.,
2015a). Moreover, several PARPi trap PARP1 onto chromatin
(Murai et al., 2012, 2014a), resulting in the collapse of replica-
tion forks (RF) that hit trapped PARP1. This leads to DNA dou-
ble-strand breaks (DSBs) and cells depend on BRCA1/2-medi-
ated repair to resolve these DSBs in an error-free way. Hence,
PARP1 inhibition causes synthetic lethality in tumors with de-
fects in homologous recombination (HR) (Bryant et al., 2005;
Farmer et al., 2005). Indeed, this lethality was also observed
in mouse models for BRCA1/2-mutated breast cancer (Evers
et al., 2008; Rottenberg et al., 2008) as well as in patients
with BRCA1/2 mutations who developed breast or ovarian
cancer (Audeh et al., 2010; Fong et al., 2009; Tutt et al.,
2010). On the basis of these positive clinical results, three
different PARPi were recently approved as a monotherapy for
the treatment of BRCA1/2-mutated ovarian cancers (Ohmoto
and Yachida, 2017).
Drug resistance often follows the introduction of therapeutics
in the clinic, and unfortunately PARPi are no exception (Audeh
et al., 2010; Fong et al., 2009). Using cell lines and mouse
models, several mechanisms of PARPi resistance have been
identified, including upregulation of the P-glycoprotein (P-gp;
also known as ABCB1) drug efflux transporter (Evers et al.,
2008; Rottenberg et al., 2008) and restoration of HR activity (re-
viewed in Annunziato et al., 2016). While the clinical significance
of P-gp-driven resistance remains controversial, HR restoration
has been observed in human tumors that re-established
BRCA1/2 function (Edwards et al., 2008; Swisher et al., 2008).
Nevertheless, secondary BRCA1/2 mutations explain only
some of the cases of PARPi resistance (Ang et al., 2013). The
requirement of BRCA1 for HR activity can be bypassed by the
loss of the 53BP1-RIF1-REV7 pathway, as shown by various
studies (Annunziato et al., 2016). In contrast, there is no evidence
that HR can be rescued in the absence of BRCA2, suggesting
that BRCA2-deficient tumors employ distinct, HR-independent
pathways to overcome PARPi toxicity.
Little is known thus far about HR-independent resistance to
PARPi. Loss of the drug target PARP1 has been described as
a mechanism of resistance in HR-proficient cells (Pettitt et al.,
2013), but this cannot explain resistance in the PARPi target
group, since PARP1 loss causes synthetic lethality of BRCA1/
2-mutated cells (Bryant et al., 2005; Farmer et al., 2005). In
this study, we set out to determine how cells with an irrevers-
ible and complete defect in the HR pathway develop PARPi
resistance.
RESULTS
Functional Genetic Screens Identify Loss of PARG as a
PARPi Resistance Factor
To identify HR-independent mechanisms of PARPi resistance,
we carried out functional genetic screens in two types of
in vitro cultures that we derived from Brca2!/!;Trp53!/! mouse
mammary tumors from K14cre;Trp53F/F;Brca2F/F (KB2P) mice:
two-dimensional (2D) tumor cell lines (KB2P1.21, KB2P3.4) and
three-dimensional (3D) cancer organoids (ORG-KB2P26S.1)
(Jonkers et al., 2001; Evers et al., 2008; Duarte et al., 2018). In
these cells we introduced a library of 1,976 short hairpin RNA
(shRNA) constructs targeting 391 DDR-related genes (on
average five shRNAs/gene) (Xu et al., 2015b). The cells were
then selected for 3 weeks with the PARPi olaparib or AZD2461
(Figure 1A) at a concentration lethal to the parental cells (data
not shown). Sequencing of PARPi-surviving populations re-
vealed a reproducible enrichment of multiple hairpins targeting
PARG. The strong effect of PARG depletion is reflected by the
overall top score of Parg among all positively selected genes,
as determined by the MAGeCK (Model-based Analysis of
Genome-wide CRISPR-Cas9 Knockout) algorithm (Li et al.,
2014) (Figures 1B and 1C; Table S1). We applied the same
screening approach to a cell line isolated from BRCA-proficient
mouse mammary tumors from K14cre;Trp53F/F (KP) mice (Evers
et al., 2008) and also identified Parg among the top outliers. In
fact, Parg was the only common hit in both BRCA-deficient
and -proficient screens (Figures 1D and 1E). In contrast, shRNAs
targeting PARP1 were only enriched in the BRCA-proficient
KP3.33 cells (Figures 1C–1E), providing functional evidence
that PARP1 loss confers PARPi resistance in BRCA-proficient
cells, presumably by preventing PARP1 trapping, but not in
BRCA2-deficient cells that depend on PARP1 for survival.
PARG Is Frequently Lost in PARPi-Resistant KB2P
Mouse Mammary Tumors
Although high-throughput genetic screens are powerful tools for
the identification of gene candidates, in vitro conditions do not
fully recapitulate the complexity of drug response observed in
real tumors. We therefore generated a panel of KB2P mouse
mammary tumors that had acquired PARPi resistance in vivo.
For this purpose, 21 individual spontaneous KB2P carcinomas
were orthotopically transplanted into multiple syngeneic mice
to allow differential treatment of the original donor tumor. Upon
outgrowth, the tumors were either treated with vehicle control
or with the PARPi AZD2461 (Figure 2A). As expected, KB2P tu-
mors were initially highly sensitive to PARPi treatment but even-
tually developed drug resistance (Figures 2B and 2C). The
observed resistance cannot be explained by BRCA2 restoration,
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which is prevented by the irreversible intragenic deletion in
Brca2, nor by upregulation of P-gp (Figure S1A), because of
the low affinity of AZD4261 to this transporter (Jaspers et al.,
2013; Oplustil O’Connor et al., 2016).
Our extensive in vivo studies yielded a unique collection of
matched PARPi-naive (n = 21) and PARPi-resistant tumors (n =
34; for some of the donors more than one resistant tumor was
generated). We have recently shown that the resistance pheno-
type is stable upon transplantation into allografts (Duarte et al.,
2018; Ray Chaudhuri et al., 2016). We now used this collection
of tumors to identify genetic factors contributing to PARPi resis-
tance. For this purpose, we generated transcriptome (RNA
sequencing [RNA-seq]) and DNA copy-number variation (CNV)
sequencing (CNV-seq) data for all tumors and carried out an inte-
grative analysis of naive versus resistant samples (Figures 2D
and 2E). First, we identified differentially expressed genes using
the DIDS (detection of imbalanced differential signal) algorithm
(cutoff p < 0.05), which is specifically designed for the detection
of subgroup markers in heterogeneous populations (de Ronde
et al., 2013). In parallel, we selected acquired copy-number
events, present only in resistant, but not in naive, samples. Since
KB2P tumors exhibit high levels of genomic instability and
A 2D cell lines
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Figure 1. Functional shRNA-Based Screens in BRCA2-Deficient and -Proficient Cells Identify PARG as PARPi Resistance Factor
(A) Outline of the functional shRNA screen.
(B) Log ratio (fold change) versus abundance (mean of norm counts) plot representing the screening outcome in KB2P1.21 cells treated with AZD2461.
(C and D) Distribution of the one-sided p value (gene enrichment) for all 391 genes targeted by the shRNA-based library in KB2P1.21 cells (C) and KP3.33 (D) cells
upon PARPi treatment.
(E) Comparison of the screening outcome between indicated cell lines; dotted grid line indicates p value = 0.05. All p values were generated per gene with
MAGeCK software; each screen was performed and analyzed in triplicate.
See also Table S1.
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Figure 2. PARG Is Frequently Lost in KB2P Tumors That Acquired PARPi Resistance In Vivo
(A) Generation of matched PARPi-naive and -resistant KB2P tumors.
(B) Treatment response of individual KB2P tumor treated with either vehicle or AZD2461, orally for 28 consecutive days. Treatment was resumedwhen the tumors
reached a size of 100% (initial volume at the start of the treatment) and the treatment cycles were repeated until acquired resistance (black arrows mark the
beginning of repeated cycles). Graph shows relative tumor volume as a function of time.
(legend continued on next page)
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accumulate many genetic alterations, we decided to focus on
DDR-related genes, as their contribution to the PARPi response
is most plausible. We generated a list of approximately 1,800
genes that have been implicated in DDR processes (Table S2)
and combined it with the significant hits from the DIDS and
CNV analyses. The 82 genes that survived these selection
criteria were ranked based on their recurrence or correlation be-
tween expression and CNV data. To integrate these rankings, we
used three different aggregation statistics: mean aggregation,
Stuart aggregation, and robust rank aggregation (RRA) (Kolde
et al., 2012). Consistent with our in vitro screens, all three algo-
rithms placed Parg at the top of the list of gene candidates (Table
S3). Parg also ranked among the top outliers in a non-curated,
genome-wide comparison (Table S3). In our panel of 34
PARPi-resistant tumors, we observed decreased expression of
Parg in 17 tumors, and acquired copy-number loss of the Parg
locus in 22 tumors (11 deletions, 11 heterozygous loss events),
with a substantial overlap between both datasets (Figures 2F,
2G, and S1B). The difference in PARG levels between PARPi-
naive and -resistant tumors was also confirmed by immunohisto-
chemistry (IHC) (Figure 2H). Blinded semi-quantitative analysis
of the PARG staining revealed a significant difference between
resistant versus naive samples (p < 0.015, Mann-Whitney
U test). This was further validated using an ELISA assay in which
we monitored the loss of biotinylated PAR from immobilized
histones and thereby directly measured the relative activity of
endogenous PARG in 3D cancer organoids derived from
PARG-deficient PARPi-resistant tumors and PARPi-sensitive
controls (Figure 2I). As expected, PARPi-resistant organoids
showed reduced ability to degrade synthetic PAR (Figure 2I)
and overall exhibited elevated levels of endogenous PAR
(Figure 2J).
To investigate the contribution of the other candidate genes to
PARPi resistance, we performed a secondary genetic loss-of-
function screen using an shRNA library targeting the identified
candidates and 32 non-essential genes as internal controls
(Table S4). Parg was again identified as a top outlier by the
enrichment analysis in both KB2P cell lines (Figure 2K and Table
S1), suggesting that loss of PARG is one of the strongest mech-
anisms involved in PARPi resistance in our model.
To test whether PARPi-induced loss of PARG is specific to
KB2P tumors, we also studied genetic alterations in Parg in
our previously described collection of PARPi-naive and -resis-
tant BRCA1-deficient mammary tumors from K14cre;Brca1F/F;
Trp53F/F (KB1P) mice (Jaspers et al., 2013). Also in this cohort,
combined RNA-seq and CNV-seq analysis identified several
PARPi-resistant tumors with significantly lower expression and
acquired copy-number loss of Parg (Figure S1C). Taken
together, our in vivo data confirm and extend the results from
the in vitro screens and suggest that PARG depletion alleviates
PARPi toxicity.
PARGDownregulationCausesPARPi Resistance In Vitro
To validate the role of PARG depletion in PARPi resistance, we
introduced two individual shRNAs against PARG (PARG sh1,
PARG sh4) in KB2P1.21 and KB2P3.4 cells, resulting in substan-
tial decrease of Parg mRNA levels (Figures 3A and S2A) and
reduced PARG activity (Figures 3B and S2B) Consistently, ge-
netic depletion of PARG in KB2P cells led to the accumulation
of PAR under genotoxic stress induced by the alkylating agent
methyl methanesulfonate (MMS) (Figures S2C and S2D) but
did not affect Parp1 expression levels (Figure S2E).
The shRNA-mediated loss of PARG resulted in increased
resistance to the PARPi olaparib and AZD2461 in long-term clo-
nogenic survival assays. This effect was observed in cell lines
derived from both KB2P and KB1P tumor models, in which
PARPi-induced loss of PARG was observed in vivo (Figures 3C
and S3A–S3C). To exclude off-target effects of the shRNAs,
we also targeted the Parg locus in KB2P cells using CRISPR-
Cas9 technology (Figures 3D and S3D–S3F). In contrast to the
control cells, Parg-targeted cells formedmany resistant colonies
after 14 days of PARPi selection. This effect was specific to Parg
inactivation, as shown by the TIDE (Tracking of Indels by Decom-
position) analysis (Brinkman et al., 2014). In the initial tumor cell
population, roughly half of the alleles carried frameshift muta-
tions, and vehicle (DMSO) treatment did not significantly affect
allele composition. In contrast, PARPi selection resulted in a
substantial increase in frameshift disruptions (>90%), showing
that the surviving populations are predominantly PARG deficient
(Figures 3D and S3D–S3F, Table S5).
We obtained further evidence for the role of PARG in PARPi
resistance with a recently developed small-molecule PARG in-
hibitor (PARGi) PDDX-004 (PDD00017272), which is very active
against mouse PARG (James et al., 2016a). In line with this,
PDDX-004 caused a dose-dependent accumulation of nuclear
PAR upon MMS-induced DNA damage in our cell lines (Figures
S3G and S3H). Consistent with our genetic inhibition experi-
ments, the clonogenic assays in KB2P cells also showed an
increased PARPi survival upon chemical inhibition of PARG (Fig-
ures 3E and S3I). Moreover, the viability of cells exposed to the
(C) Kaplan-Meier curve showing overall survival of mice bearing KB2P tumors treated with either vehicle or AZD2461. Log rank (Mantel-Cox) p value is indicated.
(D) Flowchart illustrating the steps of multi-omics approach used for the discovery of resistance factors in a panel of KB2P tumors.
(E and F) (E) Venn diagram showing overlap of potential gene candidates identified within indicated datasets. (F) Overview of genomic alterations in Parg acquired
by a panel of 34 KB2P PARPi-resistant tumors (KB2Px-Ry: x, original donor identification [ID] number; y, ID of individual resistant tumors derived from the same
donor tumor).
(G) Correlation between Parg expression and copy-number estimation for the whole panel of KB2P tumors. Spearman correlation coefficient (r), p value, and
expression threshold generated by DIDS algorithm (gray line) are indicated.
(H) Representative images of PARG IHC staining in KB2P tumors; scale bar, 100 mm.
(I) ELISA-based PARG activity assay in tumor organoids (N, naive; R, resistant); **p < 0.01, ****p < 0.0001 (two-tailed t test); experiment repeated three times, data
presented as mean ± SD of replicates.
(J) Western blot analysis of PAR in tumor-derived organoids; data representative of two independent experiments.
(K) Enrichment analysis of the secondary genetic screen in KB2P cells: comparison of the p values for all genes targeted, shown for the cell lines indicated; one-
sided p value was determined by the MAGeCK algorithm; the screen was performed in triplicate.
See also Figure S1 and Tables S1–S4).
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Figure 3. Downregulation of PARG Causes PARPi Resistance in BRCA2-Deficient Cells In Vitro
(A and B) (A) RT-qPCR analysis of Parg expression levels in KB2P1.21 cell lines expressing indicated shRNAs; data representmean ± SD of triplicate; ****p < 0.001
(two-tailed t test). (B) PAR ELISA assay in KB2P1.21 cells; data shown as mean ± SD of triplicate, ****p < 0.001 (two-tailed t test).
(C) Representative images (left) and quantification (right) of long-term clonogenic assay with KB2P1.21 cells, treated with PARPi or untreated (DMSO). Data
represent mean ± SD of three independent repeats; **p < 0.01 (t test).
(D) Representative images (left) and TIDE quantification (right) of long-term clonogenic assay with KB2P1.21 cells expressing indicated guide RNAs.
(E) Representative images (left) and quantification (right) of long-term clonogenic assay with KB2P1.21 cells treated as indicated. The experiment was repeated
three times; data plotted as mean ± SD; p < 0.001 (ANOVA).
See also Figures S2 and S3 and Table S5.
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combination of PARPi and PARGi correlated with the degree of
PARG inhibition, while PDDX-004 alone did not affect cell growth
nor PARPi response of PARG-depleted cells (Figure S3J). In
conclusion, both genetic depletion or inactivation and chemical
inhibition of PARG lead to PARPi resistance in KB2P cells, con-
firming an important functional role of PARG in mediating PARPi
toxicity.
PARG-Depleted KB2P Cells Remain HR Deficient and
Fail to Protect Stalled RF
The sequence of events that leads to PARPi-induced death of
BRCA-deficient cells includes the inhibition of PAR synthesis,
RF collapse, and the formation of DSBs. In collaboration with
the Nussenzweig laboratory, we have recently shown that RF
protection can explain resistance in some of the PARPi-resistant
KB2P mouse mammary tumors (Ray Chaudhuri et al., 2016).
Given its role in PAR catabolism, however, we did not expect
that the tumors in which we find PARG downregulation would
correct the BRCA2 defect by protecting stalled RFs or by
BRCA2-independent restoration of HR. To verify this, we
measured the capacity of PARG-depleted KB2P cells to protect
stalled RF using DNA fiber assays. In both control and PARG
knockdown KB2P cells, the induction of replication stress re-
sulted in the degradation of nascent tracts (Figure S4A), suggest-
ing that PARG loss cannot bypass the requirement of BRCA2 for
RF stabilization. Next, we assessed the capability of KB2P cells
to form RAD51 ionizing radiation (IR)-induced foci (IRIF), a hall-
mark of HR activity. As expected, we did not detect any
RAD51 IRIF in KB2P cells, regardless of Parg expression levels
(Figures S4B and S4C). Moreover, the same phenotype was
observed in PARPi-resistant KB2P tumors, in which PARG loss
was confirmed at the genomic level (Figure S4D). These results
demonstrate that loss of PARG causes PARPi resistance inde-
pendently of BRCA2 and that resistance cannot be explained
by HR restoration or RF protection.
PARG Downregulation Rescues PARylation upon PARPi
Treatment
To assess how PARG depletion causes PARPi resistance, we
studied its effect on PARylation. Upon PARPi treatment, inhibi-
tion of PARP enzymes serves as the major barrier to PAR forma-
tion, but this is reinforced by the PARG-mediated degradation of
PAR, which acts in the same direction as PARPi. We therefore
hypothesized that PARPi alone do not fully inhibit PARP and
loss of PARG would allow sufficient PAR formation in the pres-
ence of PARPi. We tested this hypothesis by measuring endog-
enous PAR levels in KB2P cells treated with the PARPi olaparib
and the PARGi PDDX-004 (Figure 4A). To discriminate between
stabilization of pre-existing and de novo synthesized PAR, we
first incubated cells with the inhibitors for 1 hr and then exposed
them to MMS to stimulate PARP activity. As predicted, olaparib
treatment resulted in a strong reduction of PAR, already at nano-
molar doses. Inhibition of PARG overcame this reduction, and
MMS treatment led to a further increase of the PAR signal. These
data indicate that olaparib concentrations sufficient to kill cells
do not completely inhibit PARP and that this residual activity is
sufficient for PAR formation if PARG activity is suppressed. We
conclude that endogenous PARG activity is required for efficient
inhibition of PAR signaling by PARPi.
We next investigated the effect of different PARP family mem-
bers on the PARPi response using BRCA-proficient KP3.33 cells,
in which CRISPR/Cas9-mediated disruption of Parp1, Parp2, or
Parp3 was well tolerated (Figures S5A–S5C). While the PARPi
sensitivity of Parp2!/! and Parp3!/! KP3.33 cells was signifi-
cantly reduced by PARG inhibition, Parp1 depletion resulted in
partial resistance to olaparib (consistent with Murai et al.,
2012), which was not further increased by PARGi treatment (Fig-
ure S5D). This result is in line with a previous report suggesting
that up to 90% of cellular PAR results from PARP1 activity
(Kim et al., 2005) and shows that PARG-related PARPi resistance
is mainly mediated by PARP1 signaling.
PARG Inhibition Reduces PARP1-DNA Complexes
Induced by PARPi Treatment
It has been shown that PARP1 association to and dissociation
from chromatin is regulated by its PARylation (Pascal and El-
lenberger, 2015) and persistent PARP1-DNA complexes,
induced by clinical PARPi, are toxic to cells (Murai et al.,
2012). We therefore measured the levels of chromatin-bound
PARP1 in KB2P cells using a previously described trapping
assay (Murai et al., 2012). Immunoblot analysis showed ola-
parib-dependent accumulation of PARP1 in chromatin frac-
tions, which was reduced in cells expressing PARG-targeting
shRNAs (Figure 4B). Since stable PARG depletion could result
in a substantial proportion of free PARP1 in a PARylated state,
and therefore lower its affinity to chromatin, we repeated the
PARP1 trapping assay in cells exposed to short-time inhibition
of PARG (Figure 4C). Although single treatment with PDDX-004
led to decreased levels of chromatin-associated PARP1,
simultaneous inhibition of both PARP1 and PARG resulted in
PARP1 trapping comparable with olaparib alone. We further
corroborated this finding by measuring PARP1 association
kinetics at multiphoton laser-induced DNA damage sites in
U2OS cells (Figures 4D and 4E). Cells were exposed to
0.5 mM olaparib and/or the PARGi PDDX-001/PDD00017273
(1 mM) (James et al., 2016a), which alone efficiently inhibited
downstream signaling of both proteins (Figures S5E–S5G).
We utilized U2OS GFP-PARP1 cells and quantified the inten-
sities of laser tracks; first, 1 min post irradiation, when under
native conditions PARP1 accumulation reached a maximum,
and then 15 min after the induction of DNA damage, when
most of the chromatin evicted PARP1 (Figure S5H). Both ola-
parib treatment alone and the combination with PDDX-001 re-
sulted in a slight increase of chromatin-associated PARP1
15 min post irradiation (Figures 4D and 4E). Of note, even
more PARP1 protein remained associated with damaged sites
in cells exposed to PARGi only. The results, however, do not
show any evidence that PARG depletion results in more rapid
release of chromatin-bound PARP1. Taken together, our data
demonstrate that PARG depletion does not enhance PARP1
dissociation from chromatin and therefore do not diminish
PARP1 trapping per se. Instead, long-term suppression of
PARG prevents excessive PARP1 binding and thus reduces
PARPi-dependent accumulation of toxic PARP1-DNA com-
plexes. The relevance of this finding is further supported by
the fact that PARG depletion also results in resistance to tala-
zoparib, a highly potent PARP1-DNA trapping agent in clinical
use (Figure 4F).
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Figure 4. PARG Deficiency Partially Rescues PARylation and Reduces the Accumulation of PARP1-DNA Complexes
(A) ELISA PAR assay in KB2P3.4 cells treated as indicated; data shown as mean ± SD of triplicate (t test). ****p < 0.0001
(B and C) Immunoblot analysis of PARP1 in chromatin-bound fractions upon genetic (B) and chemical (C) inhibition of PARG in KB2P cells, treated as indicated;
data representative for two independent experiments.
(D and E) Representative images (left) and quantification (right) of analysis of PARP1 recruitment kinetics to multiphoton tracks in U2OS PARP1-GFP cells,
following the indicated treatments. **p < 0.01; n.s., not significant; two-tailed t test, data represented as mean ± SEM. Scale bar, 10 mm.
(F) Representative images of stained wells (right) and quantification (left) of clonogenic assay in KB2P cells expressing the indicated shRNAs and treated with
talazoparib; data presented as mean ± SD of two experiments; ***p < 0.001 (two-tailed t test).
See also Figures S4 and S5.
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PARG Depletion Alleviates PARPi-Induced DNADamage
Following different forms of genotoxic stress, PARP1 activity
has recently been shown to limit the rate of RF progression
(Sugimura et al., 2008; Ray Chaudhuri et al., 2012) by modu-
lating fork reversal and preventing premature restart of
reversed RF (Berti et al., 2013; Zellweger et al., 2015). De-
regulated RF remodeling by PARP inhibition was suggested
to contribute to the synthetic lethality of PARPi with HR de-
fects, as it increases the fraction of SSBs being processed
into DSBs (Neelsen and Lopes, 2015). As shown in Figure 5A,
we confirmed that PARPi treatment increases the DNA fiber
track length upon induction of DNA damage with MMS or
camptothecin (CPT). When PARG was also inhibited in these
cells, the track length was significantly decreased, suggest-
ing that PARG depletion prevents unrestrained RF progres-
sion in PARPi-treated cells (Figures 5A and S5I). Concomi-
tantly, PARG inhibition reduced the formation of DSBs in
these cells, as measured by the neutral comet assay (Figures
5B and S5J).
Given the role of PARP1 in DNA repair, we next investigated
the PARP1-mediated recruitment of the scaffold protein
XRCC1, a PAR interactor and a key player in the BER pathway
(Nazarkina et al., 2007). To study the effects of PARPi and/or
PARGi on XRCC1 recruitment, we applied the laser micro-irra-
diation assay to U2OS cells expressing a XRCC1-GFP fusion
protein. We found that under drug-free conditions XRCC1-
GFP was rapidly recruited to sites of laser-induced DNA dam-
age (Figures 5C and 5D). Although a large proportion of the pro-
tein dissociated from chromatin within 60min after irradiation, a
substantial amount of XRCC1-GFP remained at the sites of
DNA damage. In line with previous reports (Kim et al., 2015),
treatment of cells with the PARPi olaparib abrogated XRCC1-
GFP localization to laser-inflicted damage (Figures 5C and
5D). Inhibition of PARG mitigated the inhibitory effect of ola-
parib, however, and partially rescued XRCC1-GFP recruitment.
Importantly, the quantitative analysis of laser track intensities
showed that the restored accumulation, although delayed in
time, resulted in a similar retention of XRCC1-GFP at 1 hr
post irradiation as in the control cells (Figures 5C and 5D).
This effect of PARGi is specific to PARylation-induced recruit-
ment of DNA repair factors, as we did not observe any differ-
ences in chromatin association of MDC1, which localizes to
damaged sites in a PARP1-independent manner (Yan et al.,
2013) (Figure 5E). As a readout for PARP1 function in the repair
of SSBs, we employed the previously described Fast Micro-
method SSB assay (Schro¨der et al., 2006). Consistent with
our previous results, Parg-depleted cells exhibited increased
capacity to repair SSBs in comparison with control cells (Fig-
ure 5F). This was further confirmed in cells exposed to olaparib
for 24 hr. Immunofluorescence (IF) analysis of gH2AX foci re-
vealed that Parg-depleted cells accumulated less olaparib-
induced DNA damage (Figure 5G).
Based on our data, we conclude that PARG suppression
not only reduces PARP1-DNA complexes but also rescues
controlled RF progression and promotes the recruit-
ment of DNA repair enzymes to sites of damage in cells
exposed to PARPi. Altogether, this leads to a reduction of
PARPi-induced DNA damage and improved PARPi survival
(Figure 5H).
PARG Deficiency Overcomes PARPi Toxicity in Human
Cancer Cells
The anticancer efficacy of PARPi has been validated in various
clinical studies and several PARPi were recently approved for
the treatment of patients with BRCA1/2-mutated tumors. We
therefore determined whether PARG depletion confers PARPi
resistance in human cancer cells by introducing two individual
shRNAs targeting PARG in BRCA1-mutated SUM149PT (car-
rying a protein-truncating 2288delT mutation) and BRCA2-defi-
cient DLD-1 cells. Both shRNAs efficiently suppressed PARG
expression and conferred resistance to olaparib (Figures 6A,
6B, and S6A). Similarly, chemical inhibition of PARG led to
increased survival of both cell lines in the presence of PARPi (Fig-
ures S6B and S6C).
Given that PARG loss causes PARPi resistance independently
of BRCA1/2, we extended our analysis to a recently published
pharmacogenomics dataset of 1,001 human cancer cell lines
(Iorio et al., 2016). In particular, we assessed the correlation be-
tween half maximal inhibitory concentration (IC50) values of
PARPi and gene expression levels of 1,800 DDR-related factors
(Table S2). Gene expression data and drug responses to four
different PARPi (olaparib, veliparib, rucaparib, and talazoparib)
were available for 935 cell lines from this panel. Statistical anal-
ysis revealed a significant negative association between PARG
expression and IC50 values of all four PARPi (Figures 6C and
S6D); i.e., higher PARG RNA levels were related to increased
sensitivity to these drugs. A similar negative association was
also observed for PARP1 gene expression, in agreement with
the concept that more PARP1 leads to more trapping of
PARP1 onto DNA in the presence of PARPi.
PARG Depletion Occurs in Triple-Negative Breast and
Serous Ovarian Cancer
To further assess the clinical relevance of PARG depletion, we
measured the heterogeneity of PARG expression in large sec-
tions of 56 treatment-naive triple-negative human breast cancer
(TNBC) biopsies from high-risk women eligible for PARPi treat-
ment (Cabezo´n et al., 2013; Gromova et al., 2015). IHC analysis
(Figures 6D, 6E, and S6E) revealed that, although PARG protein
was expressed in a vast majority of the biopsies, PARG-negative
areaswere found in a sizable proportion of samples. Specifically,
29 (52%) and 14 (25%) out of 56 cancers showed lack of PARG in
areas corresponding to >10% and >20% of the tumor, respec-
tively. Moreover, PARG-negative cells were positive for PAR,
and in some of the samples PAR levels were substantially
increased (Figure 6E). Of note, the variable degree of PAR could
also reflect the degree of the endogenous DNA damage among
the cases, as PARP enzymes are activated by DNA damage and
these patients did not receive any genotoxic therapy. A similar
PARG expression spectrumwas also found in a cohort of serous
ovarian carcinomas (Moudry et al., 2016), a cancer type that has
been recently approved for PARPi treatment (Figures 6D and
S6F). Taken together, our data show that PARG-depleted cells
pre-exist in a substantial proportion of clinically relevant tumors
and could potentially be selected by PARPi treatment.
PARG Suppression Results in Acquired Vulnerabilities
Molecular alterations that render cells resistant to targeted ther-
apies may also cause synthetic dependencies, which in turn
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could be exploited therapeutically to prevent cancer progres-
sion. Perturbed PAR signaling due to downregulation of PARG
has been shown to increase the sensitivity to IR (Ame´ et al.,
2009). Susceptibility to IR is also one of the characteristics of
cells with dysfunctional BRCA1/2 proteins (Kan and Zhang,
2015). We therefore set out to determine whether PARG sup-
pression could potentiate IR toxicity in BRCA1/2-mutated cells.
For this purpose, SUM149PT cells with shRNA-mediated PARG
knockdown were exposed to a range of IR doses and grown for
another 7 days. Viability measures showed increased IR sensi-
tivity of PARG-depleted cells in comparison with control popula-
tions (Figure 6F). Furthermore, dose-dependent sensitization
was also achieved by chemical inhibition of PARG in SUM149PT,
BRCA2-deficient DLD-1, and KB2P cells (Figures 6G, 6H, and
S6G). Notably, we also observed synergistic effects between
PARG inhibition and treatment with temozolomide (Figures 6I
and S6H), an alkylating agent that has been previously shown
to potentiate PARPi toxicity (Murai et al., 2014b).
Together, these results illustrate that PARG suppression,
although detrimental to PARPi efficacy, provides therapeutic vul-
nerabilities that could be used to target resistant tumors.
DISCUSSION
In this study, we show that loss of PARG is a frequent mecha-
nism of PARPi resistance in Brca2-mutated tumors. Our data
provide an HR-independent mechanism for tumor cells to adapt
their DDR in order to escape the lethal effects of PARPi. PARG is
the main enzyme responsible for degrading nuclear PAR and
thereby counteracting the action of PARP enzymes. Hence,
PARG works in the same direction as PARPi and prevents PAR
accumulation. Our finding that PARG depletion causes PARPi
resistance in BRCA2-deficient tumors highlights an important
aspect of PARPi therapy: the endogenous PARG activity in tu-
mor cells is crucial for therapy success. As PARPi do not fully
block PARP activity, loss of PARG activity is sufficient to restore
PAR formation and rescue downstream signaling of PARP1.
Within the PARP family of ADP-ribosyltransferases, three fam-
ily members, PARP1, PARP2, and PARP3, have been linked to
DNA repair (Sousa et al., 2012). PARP1 is the most abundant
of these and has been shown to play critical roles in the DDR
(De Lorenzo et al., 2013). Upon DNA damage, RFs are rapidly
and globally reversed and are maintained in the reversed state
by transient PARP-mediated inhibitory ADP ribosylation of
RECQ1 helicase, the enzymatic activity specifically required for
restart of reversed RFs (Berti et al., 2013; Zellweger et al.,
2015). In this way, PARP1 represents a molecular switch to con-
trol transient fork reversal and RF restart following genotoxic
stress (Zellweger et al., 2015). Neelsen and Lopes (2015) there-
fore suggested that the synthetic lethality of PARPi with HR de-
fects results not only from an increasing load of SSBs but also
from a greater fraction of these lesions being processed into
DSBs. Whereas untreated cells gain extra time to repair DNA
damage through RF reversal, PARPi-treated cells are unable to
reverse forks efficiently, resulting in increased DNA breakage
and the requirement for HR-mediated DSB repair. In line
with this hypothesis, we found that PARG depletion restores
controlled RF progression in the presence of PARPi and reduces
subsequent DNA damage. We also found a mechanism at the
level of DNA repair that contributes to PARPi resistance induced
by PARG loss: PAR stabilization rescues the recruitment of the
downstream scaffolding protein XRCC1, which is known to bring
together a variety of components required for efficient SSB
repair (Horton et al., 2008).
In BRCA-proficient tumors, the toxic effect of PARPi can also
be counteracted by the loss of the drug target PARP1. Consis-
tent with the data of Pettitt et al. (2013), we found a significant
enrichment for Parp1-targeting shRNAs in our drug resistance
screen in BRCA-proficient mammary tumor cells. In accordance
with the concept of synthetic lethality, however, this hit did not
show up when we screened BRCA2-deficient mammary tumor
cells. Previous screens in BRCA1-deficient tumor cells also did
not yield Parp1 as a hit (Xu et al., 2015b).
Most PARPi do not only block the catalytic activity of PARP1
but also induce toxic PARP1-DNA complexes. Our study shows
that PARG inhibition reduces the amount of trapped PARP1 by
preventing its excessive binding. This result underscores the
delicate balance between enzymatic PARP1 activity and its
toxicity when trapped on DNA.
Since PAR synthesis and degradation go hand in hand in
orchestrating the DNA damage response, the use of PARGi
has been put forward for the treatment of cancers with DDR de-
fects (Fauzee et al., 2010), and the possibility of a synthetic lethal
interaction between PARG and BRCA proteins has received
considerable interest. However, several studies that addressed
this question have produced contradictory results (Fathers
et al., 2012; Noll et al., 2016; Gravells et al., 2017), which suggest
that sensitivity to PARG depletion may depend on the cell line
Figure 5. PARG Inhibition Alleviates PARPi-Induced DNA Damage
(A) RF progression assay in U2OS cells exposed to indicated treatments; the experiment was repeated twice; box extends from 25th to 75th percentile, with a
middle line representing the median and whiskers drawn down to the 10th percentile and up to the 90th; Mann-Whitney U test; ****p < 0.001; n.s., not significant.
(B) Neutral comet assay in U2OS cells treated as in (A); Mann-Whitney U test, ****p < 0.001, data shown as mean ± SD of a replicate; the experiment was
repeated twice.
(C and D) Representative images (C) and quantification (D) of time course analysis of GFP-XRCC1 recruitment in U2OS cells treated as indicated; **p < 0.01; n.s.,
not significant; two-tailed unpaired t test; data represent mean ± SEM of three independent experiments. Scale bar, 10 mm.
(E) Quantification of MDC1 tracks following immunostaining; statistical analysis as in (D).
(F) SSB assay in KB2P cells, treated as indicated; SSF, strand scission factor; data representative for two independent experiments, shown as mean ± SD of a
replicate; two-tailed unpaired t test; *p < 0.05; n.s., not significant.
(G) IF analysis of gH2AX foci in KB2P cells, treated as indicated; statistical analysis as in (F); **p < 0.01; *p < 0.05.
(H) Proposedmodel: in the presence of PARPi, PARP1maintains residual activity but is counteracted by PARG. Loss of PARG leads to stabilization of PAR chains
and, consequently, limits accumulation of toxic PARP-DNA complexes, prevents unrestrained RF progression, and promotes the recruitment of the downstream
factors. Together, this results in reduced PARPi-induced DNA damage and improves PARPi survival.
See also Figure S5.
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and the degree of PARG suppression. Importantly, Koh et al.
(2004) showed that PARG depletion, although embryonically le-
thal, can be tolerated in embryonic stem cells cultured in the
presence of PARPi. In our cell lines, both genetic depletion and
chemical inhibition of PARG were well tolerated and did not
affect cellular viability. Moreover, homozygous loss of Parg
was acquired in vivo in a substantial fraction of KB2P tumors.
PARG-negative clones were also found in a sizable proportion
of human high-risk TNBCs or serous ovarian cancers, potential
target groups for PARPi treatment due to the increased presence
of HR-deficient cancers. Taken together, these data suggest that
PARG-negative clones can be specifically selected by PARPi
treatment and modulate therapy response.
While the clinical application of PARPi has initially focused on
BRCA1/2-mutated tumors, the therapeutic scope of these
drugs is now being extended to other molecular defects (re-
viewed in Lord and Ashworth, 2017). Since PARG acts directly
at PAR structures and independently of the HR pathway, stabi-
lization of PARylation via PARG suppression might represent a
generic mechanism of PARPi resistance, relevant for a broad
spectrum of cancers. Although this is bad news for the clinical
use of PARPi, loss of PARG can also be exploited as a potential
Achilles’ heel for cancer treatment, as it confers sensitivity to IR
(Ame´ et al., 2009). Our data indeed show that PARG suppres-
sion potentiates the toxicity of radiation therapy in BRCA-defi-
cient cells. Additionally, we show that PARG inhibition syner-
gizes with temozolomide, a chemotherapeutic agent that is
now being evaluated in the clinic in combination with PARPi
(Dre´an et al., 2016).
Our research has yielded a collection of matched PARPi-
naive and -resistant Brca2!/! mouse mammary tumors, which
can be further utilized in a search for additional resistance
mechanisms. Although PARG loss was observed in the majority
of the PARPi-resistant KB2P tumors, it cannot explain resis-
tance in all cases. Three other candidates, Rps6ka6, Socs4,
andPbrm1, were validated as additional significant hits in a sec-
ondary screen. Since all three of these genes are connected to
chromatin, it will be interesting to understand the underlying
mechanism of how they affect PARPi response in a follow-
up study.
In collaboration with the Durocher and Lord laboratories, we
have recently identified that PARPi resistance can also be
caused by loss of the Shieldin (SHLD) complex, which acts
downstream of 53BP1 in blocking DNA end resection (Noorder-
meer et al., manuscript submitted). Importantly, loss of the SHLD
complex is not a generic PARPi resistance mechanism, since it
causes PARPi resistance specifically in BRCA1- but not in
BRCA2-deficient cells. In contrast, loss of PARG explains PARPi
resistance in both BRCA1- and BRCA2-mutated tumors, as it
operates independently of the HR pathway.
Taken together, our findings suggest that PARG is an impor-
tant mediator of PARPi response. The presence of PARG-nega-
tive cells in treatment-naive tumors from the clinically relevant
groups of high-risk women suggests that PARG loss should be
assessed as a potential cause of clinical PARPi resistance. In
this case, measurement of PARG activity should further improve
clinical decisionmaking for patients with tumors that lack homol-
ogy-directed DNA repair.
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